| Year |
Citation |
Score |
| 2023 |
Akgöl K, van Merendonk LN, Barkman HJ, van Balen DE, van den Hoek HL, Klous MG, Hendrikx JJ, Huitema AD, Beijnen JH, Nuijen B. Redispensing of expensive oral anticancer medicines: A practical application. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 10781552231176199. PMID 37192749 DOI: 10.1177/10781552231176199 |
0.654 |
|
| 2022 |
van der Heijden L, van Nuland M, Beijnen J, Huitema A, Dorlo T. A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens. Clinical and Translational Science. PMID 36419385 DOI: 10.1111/cts.13446 |
0.719 |
|
| 2022 |
Embaby A, van Merendonk L, Steeghs N, Beijnen J, Huitema A. Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose? Frontiers in Oncology. 12: 940582. PMID 36185303 DOI: 10.3389/fonc.2022.940582 |
0.63 |
|
| 2021 |
Joosten SEP, Wellenstein M, Koornstra R, van Rossum A, Sanders J, van der Noort V, Ferrandez MC, Harkes R, Mandjes IAM, Rosing H, Huitema A, Beijnen JH, Wesseling J, van Diest PJ, Horlings HM, et al. IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women. Npj Breast Cancer. 7: 138. PMID 34671036 DOI: 10.1038/s41523-021-00344-3 |
0.657 |
|
| 2021 |
Geenen JJ, Dackus GM, Schouten PC, Pluim D, Marchetti S, Sonke GS, Jóźwiak K, Huitema AD, Beijnen JH, Schellens JH, Linn SC. A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer. International Journal of Cancer. PMID 33539540 DOI: 10.1200/Jco.2019.37.15_Suppl.3118 |
0.754 |
|
| 2021 |
Ten Ham RMT, van Nuland M, Vreman RA, de Graaf LG, Rosing H, Bergman AM, Huitema ADR, Beijnen JH, Hövels AM. Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 24: 121-128. PMID 33431146 DOI: 10.1016/J.Jval.2020.04.1838 |
0.336 |
|
| 2020 |
van Brummelen EMJ, Huijberts S, van Herpen C, Desar I, Opdam F, van Geel R, Marchetti S, Steeghs N, Monkhorst K, Thijssen B, Rosing H, Huitema A, Beijnen J, Bernards R, Schellens J. Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. The Oncologist. 26: 290-e545. PMID 33296125 DOI: 10.1002/onco.13631 |
0.728 |
|
| 2020 |
de Jong KA, van Breugel SJ, Hillebrand MJ, Rosing H, Huitema AD, Beijnen JH. Bottom-up sample preparation for the LC-MS/MS quantification of anti-cancer monoclonal antibodies in bio matrices. Bioanalysis. PMID 32975434 DOI: 10.4155/bio-2020-0204 |
0.65 |
|
| 2020 |
Martínez-Chávez A, Tibben MM, Broeders J, Rosing H, Schinkel AH, Beijnen JH. Development and validation of an LC-MS/MS method for the quantitative analysis of milciclib in human and mouse plasma, mouse tissue homogenates and tissue culture medium. Journal of Pharmaceutical and Biomedical Analysis. 190: 113516. PMID 32784092 DOI: 10.1016/J.Jpba.2020.113516 |
0.357 |
|
| 2020 |
Palić S, Kip AE, Beijnen JH, Mbui J, Musa A, Solomos A, Wasunna M, Olobo J, Alves F, Dorlo TPC. Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa. The Journal of Antimicrobial Chemotherapy. PMID 32780098 DOI: 10.1093/Jac/Dkaa314 |
0.372 |
|
| 2020 |
Hendrikx JJMA, Stuurman FE, Song JY, de Weger VA, Lagas JS, Rosing H, Beijnen JH, Schinkel AH, Schellens JHM, Marchetti S. No relation between docetaxel administration route and high-grade diarrhea incidence. Pharmacology Research & Perspectives. 8: e00633. PMID 32725720 DOI: 10.1002/Prp2.633 |
0.368 |
|
| 2020 |
IJzerman NS, Groenland SL, Koenen AM, Kerst M, van der Graaf WTA, Rosing H, Beijnen JH, Huitema ADR, Steeghs N. Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice. European Journal of Cancer (Oxford, England : 1990). 136: 140-148. PMID 32688207 DOI: 10.1016/J.Ejca.2020.05.025 |
0.357 |
|
| 2020 |
Groenland SL, Geel DR, Janssen JM, de Vries N, Rosing H, Beijnen JH, Burgers JA, Smit EF, Huitema ADR, Steeghs N. Exposure-response analyses of anaplastic lymphoma kinase inhibitors crizotinib and alectinib in non-small-cell lung cancer patients. Clinical Pharmacology and Therapeutics. PMID 32686074 DOI: 10.1002/Cpt.1989 |
0.378 |
|
| 2020 |
Rood JJM, Jamalpoor A, van Hoppe S, van Haren MJ, Wasmann RE, Janssen MJ, Schinkel AH, Masereeuw R, Beijnen JH, Sparidans RW. Extrahepatic metabolism of ibrutinib. Investigational New Drugs. PMID 32623551 DOI: 10.1007/S10637-020-00970-X |
0.316 |
|
| 2020 |
Martínez-Chávez A, Rosing H, Gan C, Wang Y, Schinkel AH, Beijnen JH. Bioanalytical method for the simultaneous quantification of irinotecan and its active metabolite SN-38 in mouse plasma and tissue homogenates using HPLC-fluorescence. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1149: 122177. PMID 32464539 DOI: 10.1016/J.Jchromb.2020.122177 |
0.33 |
|
| 2020 |
Roosendaal J, Groenland SL, Rosing H, Lucas L, Venekamp N, Nuijen B, Huitema ADR, Beijnen JH, Steeghs N. Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose. European Journal of Clinical Pharmacology. PMID 32430518 DOI: 10.1007/S00228-020-02888-Y |
0.353 |
|
| 2020 |
Şentürk R, Wang Y, Schinkel AH, Beijnen JH, Sparidans RW. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1147: 122131. PMID 32416592 DOI: 10.1016/J.Jchromb.2020.122131 |
0.355 |
|
| 2020 |
Janssen JM, Dorlo TPC, Beijnen JH, Huitema ADR. Evaluation of Extrapolation Methods to Predict Trough Concentrations to Guide Therapeutic Drug Monitoring of Oral Anticancer Drugs. Therapeutic Drug Monitoring. 42: 532-539. PMID 32384536 DOI: 10.1097/Ftd.0000000000000767 |
0.361 |
|
| 2020 |
Roosendaal J, Jacobs BAW, Pluim D, Rosing H, de Vries N, van Werkhoven E, Nuijen B, Beijnen JH, Huitema ADR, Schellens JHM, Marchetti S. Phase I pharmacological study of continuous chronomodulated capecitabine treatment. Pharmaceutical Research. 37: 89. PMID 32382808 DOI: 10.1007/S11095-020-02828-6 |
0.374 |
|
| 2020 |
Yu H, Janssen JM, de Weger VA, Nuijen B, Stuurman RE, Marchetti S, Schellens JHM, Beijnen JH, Dorlo TPC, Huitema ADR. Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir. Investigational New Drugs. PMID 32306204 DOI: 10.1007/S10637-020-00935-0 |
0.413 |
|
| 2020 |
Roosendaal J, Rosing H, Beijnen JH. Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in Oncology. Drugs in R&D. PMID 32300967 DOI: 10.1007/S40268-020-00304-5 |
0.361 |
|
| 2020 |
Roosendaal J, Venekamp N, Lucas L, Rosing H, Beijnen JH. Development and validation of an LC-MS/MS method for the quantification of imatinib and imatinib-d8 in human plasma for the support of an absolute bioavailability microdose trial. Die Pharmazie. 75: 136-141. PMID 32295689 DOI: 10.1691/Ph.2020.9150 |
0.316 |
|
| 2020 |
Li W, Perpinioti N, Schinkel AH, Beijnen JH, Sparidans RW. Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1144: 122098. PMID 32278292 DOI: 10.1016/J.Jchromb.2020.122098 |
0.338 |
|
| 2020 |
Wang J, Bruin MAC, Gan C, Lebre MC, Rosing H, Beijnen JH, Schinkel AH. Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice. International Journal of Pharmaceutics. 119277. PMID 32234426 DOI: 10.1016/J.Ijpharm.2020.119277 |
0.315 |
|
| 2020 |
Roseboom IC, Thijssen B, Rosing H, Mbui J, Beijnen JH, Dorlo TPC. Highly sensitive UPLC-MS/MS method for the quantification of paromomycin in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 185: 113245. PMID 32199328 DOI: 10.1016/J.Jpba.2020.113245 |
0.352 |
|
| 2020 |
Groenland SL, van Nuland M, Bergman AM, de Feijter JM, Dezentje VO, Rosing H, Beijnen JH, Huitema ADR, Steeghs N. Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. European Journal of Cancer (Oxford, England : 1990). 130: 32-38. PMID 32172196 DOI: 10.1016/J.Ejca.2020.02.012 |
0.395 |
|
| 2020 |
Huijberts S, Wang L, de Oliveira RL, Rosing H, Nuijen B, Beijnen J, Bernards R, Schellens J, Wilgenhof S. Vorinostat in patients with resistant mutated advanced melanoma: a proof of concept study. Future Oncology (London, England). PMID 32125175 DOI: 10.2217/Fon-2020-0023 |
0.443 |
|
| 2020 |
Wang Y, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH. OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. British Journal of Pharmacology. PMID 32087611 DOI: 10.1111/Bph.15034 |
0.305 |
|
| 2020 |
Janssen JM, Dorlo TPC, Steeghs N, Beijnen JH, Hanff LM, van Eijkelenburg NKA, van der Lugt J, Zwaan CM, Huitema ADR. Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology. Clinical Pharmacology and Therapeutics. PMID 32022898 DOI: 10.1002/Cpt.1808 |
0.34 |
|
| 2020 |
Groenland SL, van Eerden RAG, Verheijen RB, de Vries N, Thijssen B, Rosing H, Beijnen JH, Koolen SLW, Mathijssen RHJ, Huitema ADR, Steeghs N. Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients. Clinical Pharmacokinetics. PMID 32020530 DOI: 10.1007/S40262-020-00863-5 |
0.349 |
|
| 2020 |
de Vries Schultink AHM, Bol K, Doornbos RP, Murat A, Wasserman E, Dorlo TPC, Schellens JHM, Beijnen JH, Huitema ADR. Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors. Clinical Pharmacokinetics. PMID 32006223 DOI: 10.1007/S40262-020-00858-2 |
0.306 |
|
| 2020 |
Van Nuland M, Rosing H, Thijssen B, Burgers JA, Huitema ADR, Marchetti S, Schellens JHM, Beijnen JH. Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose. Clinical Pharmacology in Drug Development. PMID 31970932 DOI: 10.1002/Cpdd.774 |
0.392 |
|
| 2020 |
Henricks LM, Opdam FL, Beijnen JH, Cats A, Schellens JHM. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: 2915-2922. PMID 29045513 DOI: 10.1093/Annonc/Mdx411 |
0.39 |
|
| 2020 |
Vermunt M, Robbrecht D, Devriese L, Janssen J, Keessen M, Eskens F, Beijnen JH, Mehra N, Bergman AM. ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastasized castration-resistant prostate cancer (mCRPC): A multicenter phase I study. Journal of Clinical Oncology. 38: 79-79. DOI: 10.1200/Jco.2020.38.6_Suppl.79 |
0.392 |
|
| 2020 |
Huijberts S, Brummelen EV, Van Herpen CM, Desar IM, Opdam F, Geel RV, Marchetti S, Steeghs N, Monkhorst K, Thijssen B, Rosing H, Huitema A, Beijnen JH, Bernards R, Schellens JHM. Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer. Journal of Clinical Oncology. 38: 3613-3613. DOI: 10.1200/Jco.2020.38.15_Suppl.3613 |
0.385 |
|
| 2020 |
Groenland SL, Eerden RAGv, Koolen SLW, Moes DJAR, Imholz A, Wilgenhof S, Graaf WTAVD, Gelderblom H, Beijnen JH, Mathijssen RHJ, Huitema A, Steeghs N. Therapeutic drug monitoring of pazopanib: Using cost-neutral PK-guided interventions to optimize exposure. Journal of Clinical Oncology. 38: 3598-3598. DOI: 10.1200/Jco.2020.38.15_Suppl.3598 |
0.327 |
|
| 2020 |
Chavez AM, Tibben MM, Lebre MC, Rosing H, Beijnen JH, Schinkel AH. Abstract 6322: The role of multidrug efflux transporters and CYP3A in the pharmacokinetics and tissue distribution of abemaciclib and its active metabolites Cancer Research. 80: 6322-6322. DOI: 10.1158/1538-7445.Am2020-6322 |
0.356 |
|
| 2019 |
Bruin MAC, de Vries N, Lucas L, Rosing H, Huitema ADR, Beijnen JH. Development and validation of an integrated LC-MS/MS assay for therapeutic drug monitoring of five PARP-inhibitors. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1138: 121925. PMID 31915109 DOI: 10.1016/J.Jchromb.2019.121925 |
0.34 |
|
| 2019 |
Li W, Sparidans R, El-Lari M, Wang Y, Lebre MC, Beijnen JH, Schinkel AH. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). International Journal of Pharmaceutics. 118842. PMID 31759109 DOI: 10.1016/J.Ijpharm.2019.118842 |
0.337 |
|
| 2019 |
Crombag MBS, Dorlo TPC, van der Pan E, van Straten A, Bergman AM, van Erp NP, Beijnen JH, Huitema ADR. Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study. Pharmaceutical Research. 36: 181. PMID 31732882 DOI: 10.1007/S11095-019-2706-4 |
0.311 |
|
| 2019 |
Knikman JE, Rosing H, Guchelaar HJ, Cats A, Beijnen JH. A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices. Biomedical Chromatography : Bmc. e4732. PMID 31691313 DOI: 10.1002/Bmc.4732 |
0.332 |
|
| 2019 |
van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, de Bono JS, Schellens JHM. Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1). Investigational New Drugs. PMID 31667659 DOI: 10.1007/S10637-019-00856-7 |
0.397 |
|
| 2019 |
van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, de Bono JS, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, De Grève J, Schellens JHM. Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Investigational New Drugs. PMID 31637669 DOI: 10.1007/S10637-019-00857-6 |
0.382 |
|
| 2019 |
van Nuland M, Groenland SL, Bergman AM, Steeghs N, Rosing H, Venekamp N, Huitema ADR, Beijnen JH. Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 23: 244-251. PMID 31611636 DOI: 10.1038/S41391-019-0179-5 |
0.352 |
|
| 2019 |
Roosendaal J, Rosing H, Lucas L, Gebretensae A, Huitema ADR, van Dongen MG, Beijnen JH, Oganesian A. Mass balance and metabolite profiling of C-guadecitabine in patients with advanced cancer. Investigational New Drugs. PMID 31605293 DOI: 10.1007/S10637-019-00854-9 |
0.409 |
|
| 2019 |
van Nuland M, Bergman AM, Rosing H, de Vries N, Huitema ADR, Beijnen JH. Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer. Pharmacotherapy. PMID 31596947 DOI: 10.1002/Phar.2339 |
0.306 |
|
| 2019 |
Yu H, Janssen JM, Sawicki E, van Hasselt JGC, de Weger VA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR. A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development. Journal of Clinical Pharmacology. PMID 31595980 DOI: 10.1002/Jcph.1532 |
0.762 |
|
| 2019 |
Rood JJM, van Haren MJ, Beijnen JH, Sparidans RW. Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 177: 112871. PMID 31539712 DOI: 10.1016/J.Jpba.2019.112871 |
0.311 |
|
| 2019 |
Bruin MAC, Rosing H, Lucas L, Wang J, Huitema ADR, Schinkel AH, Beijnen JH. Development and validation of an LC-MS/MS method with a broad linear dynamic range for the quantification of tivozanib in human and mouse plasma, mouse tissue homogenates, and culture medium. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1125: 121723. PMID 31352204 DOI: 10.1016/J.Jchromb.2019.121723 |
0.343 |
|
| 2019 |
Martínez-Chávez A, van Hoppe S, Rosing H, Lebre MC, Tibben M, Beijnen JH, Schinkel AH. P-glycoprotein limits ribociclib brain exposure and CYP3A4 restricts its oral bioavailability. Molecular Pharmaceutics. PMID 31329454 DOI: 10.1021/Acs.Molpharmaceut.9B00475 |
0.326 |
|
| 2019 |
Janssen JM, Dorlo TPC, Niewerth D, Wilhelm AJ, Zwaan CM, Beijnen JH, Attarbaschi A, Baruchel A, Fagioli F, Klingebiel T, De Moerloose B, Palumbo G, von Stackelberg A, Kaspers GJL, Huitema ADR. A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clinical Pharmacokinetics. PMID 31313068 DOI: 10.1007/S40262-019-00803-Y |
0.341 |
|
| 2019 |
Li W, Tibben M, Wang Y, Lebre MC, Rosing H, Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib. International Journal of Cancer. PMID 31304590 DOI: 10.1002/Ijc.32568 |
0.322 |
|
| 2019 |
Janssen JM, de Vries N, Venekamp N, Rosing H, Huitema ADR, Beijnen JH. Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 174: 561-566. PMID 31255856 DOI: 10.1016/J.Jpba.2019.06.034 |
0.375 |
|
| 2019 |
van Nuland M, Janssen JM, van Hoek B, Rosing H, Beijnen JH, Bergman AM. Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant. Clinical Genitourinary Cancer. PMID 31248829 DOI: 10.1016/J.Clgc.2019.05.026 |
0.355 |
|
| 2019 |
de Weger VA, Stuurman FE, Koolen SL, Moes JJ, Hendrikx JJMA, Sawicki E, Thijssen B, Keessen M, Rosing H, Mergui-Roelvink M, Huitema ADR, Nuijen B, Beijnen JH, Schellens JHM, Marchetti S. A phase I dose escalation study of once weekly oral administration of docetaxel as ModraDoc001 capsule or ModraDoc006 tablet in combination with ritonavir. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31217201 DOI: 10.1158/1078-0432.Ccr-17-2299 |
0.375 |
|
| 2019 |
van Nuland M, Rosing H, Schellens JHM, Beijnen JH. Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology. Biomedical Chromatography : Bmc. e4623. PMID 31215049 DOI: 10.1002/Bmc.4623 |
0.348 |
|
| 2019 |
Martínez-Chávez A, Rosing H, Hillebrand M, Tibben M, Schinkel AH, Beijnen JH. Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry. PMID 31209549 DOI: 10.1007/S00216-019-01932-W |
0.353 |
|
| 2019 |
van Hoppe S, Jamalpoor A, Rood JJM, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (Breast Cancer Resistance Protein). Pharmacological Research. 104297. PMID 31175939 DOI: 10.1016/J.Phrs.2019.104297 |
0.306 |
|
| 2019 |
Groenland SL, Mathijssen RHJ, Beijnen JH, Huitema ADR, Steeghs N. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. European Journal of Clinical Pharmacology. PMID 31175385 DOI: 10.1007/S00228-019-02704-2 |
0.36 |
|
| 2019 |
Sparidans RW, Li W, Schinkel AH, Beijnen JH. Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1122: 78-82. PMID 31163324 DOI: 10.1016/J.Jchromb.2019.05.026 |
0.358 |
|
| 2019 |
Arnamo AH, Huitema AD, Beijnen JH, Nuijen B. Use of leftovers of monoclonal antibody products after partial extraction - A microbiological safety study. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 1078155219850297. PMID 31156055 DOI: 10.1177/1078155219850297 |
0.656 |
|
| 2019 |
Tibben MM, Huijberts S, Li W, Schinkel AH, Gebretensae A, Rosing H, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study. Journal of Pharmaceutical and Biomedical Analysis. 173: 169-175. PMID 31146172 DOI: 10.1016/J.Jpba.2019.05.037 |
0.333 |
|
| 2019 |
van Nuland M, Rosing H, Huitema ADR, Beijnen JH. Predictive Value of Microdose Pharmacokinetics. Clinical Pharmacokinetics. PMID 31030372 DOI: 10.1007/S40262-019-00769-X |
0.393 |
|
| 2019 |
van Nuland M, Venekamp N, Wouters WME, van Rossum HH, Rosing H, Beijnen JH. LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide. Journal of Pharmaceutical and Biomedical Analysis. 170: 161-168. PMID 30925273 DOI: 10.1016/J.Jpba.2019.03.043 |
0.35 |
|
| 2019 |
Dogan-Topal B, Li W, Schinkel AH, Beijnen JH, Sparidans RW. Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1110: 116-123. PMID 30802754 DOI: 10.1016/J.Jchromb.2019.02.017 |
0.35 |
|
| 2019 |
de Vries Schultink AHM, Crombag MBS, van Werkhoven E, Otten HM, Bergman AM, Schellens JHM, Huitema ADR, Beijnen JH. Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort. Cancer Medicine. PMID 30802002 DOI: 10.1002/Cam4.2003 |
0.341 |
|
| 2019 |
Roosendaal J, Wang K, Rosing H, Lucas L, Gebretensae A, Oganesian A, Schellens JHM, Beijnen JH, Lin ZJ. Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1109: 132-141. PMID 30754019 DOI: 10.1016/J.Jchromb.2019.01.011 |
0.372 |
|
| 2019 |
Crombag MBS, de Vries Schultink AHM, van Doremalen JGC, Otten HM, Bergman AM, Schellens JHM, Beijnen JH, Huitema ADR. Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice. Drugs & Aging. PMID 30734241 DOI: 10.1007/S40266-019-00643-2 |
0.301 |
|
| 2019 |
Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. PMID 30660696 DOI: 10.1016/J.Ejpb.2019.01.016 |
0.358 |
|
| 2019 |
van Nuland M, Venekamp N, de Vries N, de Jong KAM, Rosing H, Beijnen JH. Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1106: 26-34. PMID 30639947 DOI: 10.1016/J.Jchromb.2019.01.001 |
0.359 |
|
| 2019 |
Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, ... ... Beijnen JH, et al. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. European Journal of Cancer (Oxford, England : 1990). 107: 60-67. PMID 30544060 DOI: 10.1016/J.Ejca.2018.11.010 |
0.318 |
|
| 2019 |
van Waterschoot RA, Eman RM, Wagenaar E, van der Kruijssen CM, Rosing H, Beijnen JH, Schinkel AH. ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7616-7623. PMID 19996204 DOI: 10.1158/1078-0432.Ccr-09-2127 |
0.301 |
|
| 2019 |
Vermunt M, Janssen J, Vrijenhoek G, van der Poel H, Thijssen B, Beijnen J, van Triest B. Addition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients with high risk N+M0 prostate cancer Annals of Oncology. 30: v355. DOI: 10.1093/Annonc/Mdz248.056 |
0.352 |
|
| 2019 |
Huijberts SCFA, van Brummelen E, van Geel R, Opdam F, Marchetti S, Steeghs N, Pulleman S, Thijssen B, Rosing H, Monkhorst K, Huitema A, Beijnen J, Bernards R, Schellens J. Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer Annals of Oncology. 30: v178-v179. DOI: 10.1093/Annonc/Mdz244.035 |
0.306 |
|
| 2018 |
Wang J, Gan C, Retmana IA, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice. International Journal of Pharmaceutics. PMID 30553002 DOI: 10.1016/J.Ijpharm.2018.12.014 |
0.351 |
|
| 2018 |
Verheijen RB, Thijssen B, Atrafi F, Schellens JHM, Rosing H, de Vries N, Beijnen JH, Mathijssen RHJ, Steeghs N, Huitema ADR. Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1104: 234-239. PMID 30530116 DOI: 10.1016/J.Jchromb.2018.11.030 |
0.315 |
|
| 2018 |
Henricks LM, van Merendonk LN, Meulendijks D, Deenen MJ, Beijnen JH, de Boer A, Cats A, Schellens JHM. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis. International Journal of Cancer. PMID 30485432 DOI: 10.1002/Ijc.32022 |
0.31 |
|
| 2018 |
Sparidans RW, Wang Y, Schinkel AH, Schellens JHM, Beijnen JH. Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1102: 167-172. PMID 30396050 DOI: 10.1016/J.Jchromb.2018.10.023 |
0.363 |
|
| 2018 |
Jacobs BAW, Pluim D, van der Laan P, Tzani A, Beijnen JH, Schellens JHM. Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells. Nucleosides, Nucleotides & Nucleic Acids. 1-19. PMID 30285552 DOI: 10.1080/15257770.2018.1498270 |
0.329 |
|
| 2018 |
Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH. P-glycoprotein and Breast Cancer Resistance Protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability. Pharmacological Research. PMID 30253203 DOI: 10.1016/J.Phrs.2018.09.020 |
0.355 |
|
| 2018 |
van Hoppe S, Rood JJM, Buil L, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) restricts brain penetration of the Bruton's tyrosine kinase inhibitor ibrutinib while Cytochrome P450-3A (CYP3A) limits its oral bioavailability. Molecular Pharmaceutics. PMID 30247919 DOI: 10.1021/Acs.Molpharmaceut.8B00702 |
0.329 |
|
| 2018 |
de Vries Schultink AHM, Huitema ADR, Beijnen JH. Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy. Breast (Edinburgh, Scotland). 42: 38-40. PMID 30153552 DOI: 10.1016/J.Breast.2018.08.100 |
0.308 |
|
| 2018 |
Sparidans RW, Li W, Schinkel AH, Schellens JHM, Beijnen JH. Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates. Journal of Pharmaceutical and Biomedical Analysis. 161: 136-143. PMID 30149189 DOI: 10.1016/J.Jpba.2018.08.038 |
0.355 |
|
| 2018 |
Crombag MBS, van Doremalen JGC, Janssen JM, Rosing H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Oncology in a Real-world Cohort Study: Does Age Matter? British Journal of Clinical Pharmacology. PMID 30068020 DOI: 10.1111/Bcp.13725 |
0.308 |
|
| 2018 |
van Andel L, Rosing H, Schellens JH, Beijnen JH. Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment. Marine Drugs. 16. PMID 30041477 DOI: 10.3390/Md16070246 |
0.511 |
|
| 2018 |
van Andel L, Rosing H, Tibben MM, Lucas L, Lubomirov R, Avilés P, Francesch A, Fudio S, Gebretensae A, Hillebrand MJX, Schellens JHM, Beijnen JH. Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of C-plitidepsin. Cancer Chemotherapy and Pharmacology. PMID 29974200 DOI: 10.1007/S00280-018-3637-1 |
0.358 |
|
| 2018 |
Kip AE, Wasunna M, Alves F, Schellens JHM, Beijnen JH, Musa AM, Khalil EAG, Dorlo TPC. Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis. Frontiers in Cellular and Infection Microbiology. 8: 181. PMID 29911074 DOI: 10.3389/Fcimb.2018.00181 |
0.348 |
|
| 2018 |
van Andel L, Rosing H, Lubomirov R, Avilés P, Fudio S, Tibben MM, Nan-Offeringa L, Schellens JHM, Beijnen JH. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis. 158: 160-165. PMID 29883879 DOI: 10.1016/J.Jpba.2018.05.053 |
0.325 |
|
| 2018 |
Groenland SL, van Nuland M, Verheijen RB, Schellens JHM, Beijnen JH, Huitema ADR, Steeghs N. Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology. Clinical Pharmacokinetics. PMID 29862467 DOI: 10.1007/S40262-018-0683-0 |
0.417 |
|
| 2018 |
de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, van Tellingen O. Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2. Neoplasia (New York, N.Y.). 20: 710-720. PMID 29852323 DOI: 10.1016/J.Neo.2018.05.001 |
0.33 |
|
| 2018 |
Rood JJM, Dormans PJA, van Haren MJ, Schellens JHM, Beijnen JH, Sparidans RW. Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1090: 14-21. PMID 29778873 DOI: 10.1016/J.Jchromb.2018.05.011 |
0.319 |
|
| 2018 |
Kip AE, Castro MDM, Gomez MA, Cossio A, Schellens JHM, Beijnen JH, Saravia NG, Dorlo TPC. Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships. The Journal of Antimicrobial Chemotherapy. PMID 29757380 DOI: 10.1093/Jac/Dky143 |
0.367 |
|
| 2018 |
Li W, Sparidans RW, Wang Y, Lebre MC, Wagenaar E, Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and Cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. International Journal of Cancer. PMID 29744867 DOI: 10.1002/Ijc.31582 |
0.337 |
|
| 2018 |
de Vries Schultink AHM, Doornbos RP, Bakker ABH, Bol K, Throsby M, Geuijen C, Maussang D, Schellens JHM, Beijnen JH, Huitema ADR. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose. Investigational New Drugs. PMID 29728897 DOI: 10.1007/S10637-018-0593-X |
0.327 |
|
| 2018 |
Herbrink M, Groenland SL, Huitema ADR, Schellens JHM, Beijnen JH, Steeghs N, Nuijen B. Solubility and bioavailability improvement of pazopanib hydrochloride. International Journal of Pharmaceutics. 544: 181-190. PMID 29680279 DOI: 10.1016/J.Ijpharm.2018.04.037 |
0.376 |
|
| 2018 |
Spatari C, Li W, Schinkel AH, Ragno G, Schellens JHM, Beijnen JH, Sparidans RW. Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1083: 204-208. PMID 29550682 DOI: 10.1016/J.Jchromb.2018.03.014 |
0.349 |
|
| 2018 |
Milroy LG, Koning B, Scheppingen DSV, Jager NGL, Beijnen JH, Koek J, Brunsveld L. A multi-gram-scale stereoselective synthesis of Z-endoxifen. Bioorganic & Medicinal Chemistry Letters. PMID 29548575 DOI: 10.1016/J.Bmcl.2018.03.008 |
0.316 |
|
| 2018 |
Derissen EJB, Huitema ADR, Rosing H, Schellens JHM, Beijnen JH. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides. British Journal of Clinical Pharmacology. PMID 29451684 DOI: 10.1111/Bcp.13557 |
0.302 |
|
| 2018 |
van Nuland M, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH. Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma. Therapeutic Drug Monitoring. 39: 243-251. PMID 28490047 DOI: 10.1097/Ftd.0000000000000387 |
0.326 |
|
| 2017 |
van Nuland M, Hillebrand MJX, Rosing H, Burgers JA, Schellens JHM, Beijnen JH. Ultra-sensitive LC-MS/MS method for the quantification of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma for a microdose clinical trial. Journal of Pharmaceutical and Biomedical Analysis. 151: 25-31. PMID 29294409 DOI: 10.1016/J.Jpba.2017.12.048 |
0.348 |
|
| 2017 |
Verheijen RB, Thijssen B, Rosing H, Schellens JHM, Nan L, Venekamp N, Beijnen JH, Steeghs N, Huitema ADR. Fast and straightforward method for the quantification of pazopanib in human plasma using LC-MS/MS. Therapeutic Drug Monitoring. PMID 29256969 DOI: 10.1097/Ftd.0000000000000479 |
0.39 |
|
| 2017 |
van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH. Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients. Cancer Chemotherapy and Pharmacology. PMID 29181573 DOI: 10.1007/S00280-017-3474-7 |
0.328 |
|
| 2017 |
Verheijen RB, Yaqub MM, Sawicki E, van Tellingen O, Lammertsma AA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR, Hendrikse NH, Steeghs N. Molecular Imaging of ABCB1/ABCG2 Inhibition at the Human Blood Brain Barrier using Elacridar and 11C-Erlotinib PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29175983 DOI: 10.2967/Jnumed.117.195800 |
0.326 |
|
| 2017 |
Herbrink M, de Vries N, Rosing H, Huitema ADR, Nuijen B, Schellens JHM, Beijnen JH. Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs. Biomedical Chromatography : Bmc. 32. PMID 29165815 DOI: 10.1002/Bmc.4147 |
0.363 |
|
| 2017 |
Wang J, Gan C, Sparidans RW, Wagenaar E, van Hoppe S, Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. Pharmacological Research. PMID 29155017 DOI: 10.1016/J.Phrs.2017.11.006 |
0.323 |
|
| 2017 |
Geenen JJJ, Linn SC, Beijnen JH, Schellens JHM. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. Clinical Pharmacokinetics. PMID 29063517 DOI: 10.1007/S40262-017-0587-4 |
0.3 |
|
| 2017 |
Herbrink M, Thijssen B, Hillebrand MJX, Rosing H, Schellens JHM, Nuijen B, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 148: 259-264. PMID 29059615 DOI: 10.1016/J.Jpba.2017.10.009 |
0.329 |
|
| 2017 |
van Nuland M, Rosing H, de Vries J, Ovaa H, Schellens JHM, Beijnen JH. An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1068: 119-124. PMID 29059586 DOI: 10.1016/J.Jchromb.2017.10.033 |
0.365 |
|
| 2017 |
Verheijen RB, Swart LE, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. Cancer Chemotherapy and Pharmacology. PMID 29051995 DOI: 10.1007/S00280-017-3463-X |
0.322 |
|
| 2017 |
Herbrink M, Vromans H, Schellens J, Beijnen J, Nuijen B. Thermal stability study of crystalline and novel spray-dried amorphous nilotinib hydrochloride. Journal of Pharmaceutical and Biomedical Analysis. 148: 182-188. PMID 29040935 DOI: 10.1016/J.Jpba.2017.10.001 |
0.412 |
|
| 2017 |
de Weger VA, Stuurman FE, Hendrikx JJMA, Moes JJ, Sawicki E, Huitema ADR, Nuijen B, Thijssen B, Rosing H, Keessen M, Mergui-Roelvink M, Beijnen JH, Schellens JHM, Marchetti S. A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir. European Journal of Cancer (Oxford, England : 1990). 86: 217-225. PMID 29031170 DOI: 10.1016/J.Ejca.2017.09.010 |
0.348 |
|
| 2017 |
Dorlo TPC, Kip AE, Younis BM, Ellis SJ, Alves F, Beijnen JH, Njenga S, Kirigi G, Hailu A, Olobo J, Musa AM, Balasegaram M, Wasunna M, Karlsson MO, Khalil EAG. Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study. The Journal of Antimicrobial Chemotherapy. PMID 28961737 DOI: 10.1093/Jac/Dkx283 |
0.327 |
|
| 2017 |
de Gooijer MC, Zhang P, Weijer R, Buil LCM, Beijnen JH, van Tellingen O. The impact of P-glycoprotein and Breast Cancer Resistance Protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. International Journal of Cancer. PMID 28921565 DOI: 10.1002/Ijc.31052 |
0.347 |
|
| 2017 |
Janssen JM, Zwaan CM, Schellens JHM, Beijnen JH, Huitema ADR. Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium. European Journal of Cancer (Oxford, England : 1990). 85: 78-85. PMID 28892776 DOI: 10.1016/J.Ejca.2017.07.050 |
0.354 |
|
| 2017 |
Kort A, van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Brain accumulation of ponatinib and its active metabolite N-desmethyl ponatinib is limited by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Molecular Pharmaceutics. PMID 28880088 DOI: 10.1021/Acs.Molpharmaceut.7B00257 |
0.346 |
|
| 2017 |
Retmana IA, Wang J, Schinkel AH, Schellens JHM, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1061: 300-305. PMID 28772226 DOI: 10.1016/J.Jchromb.2017.07.034 |
0.352 |
|
| 2017 |
Verheijen RB, Atrafi F, Schellens JHM, Beijnen JH, Huitema ADR, Mathijssen RHJ, Steeghs N. Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. Clinical Pharmacokinetics. PMID 28762135 DOI: 10.1007/S40262-017-0582-9 |
0.366 |
|
| 2017 |
Kip AE, Schellens JHM, Beijnen JH, Dorlo TPC. Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs. Clinical Pharmacokinetics. PMID 28756612 DOI: 10.1007/S40262-017-0570-0 |
0.389 |
|
| 2017 |
Hendrikx JJMA, Haanen JBAG, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH. Fixed Dosing of Monoclonal Antibodies in Oncology. The Oncologist. PMID 28754722 DOI: 10.1634/Theoncologist.2017-0167 |
0.33 |
|
| 2017 |
Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. Clinical Pharmacology and Therapeutics. PMID 28699160 DOI: 10.1002/Cpt.787 |
0.354 |
|
| 2017 |
van Andel L, Rosing H, Fudio S, Avilés P, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH. Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine. Journal of Pharmaceutical and Biomedical Analysis. 145: 137-143. PMID 28662481 DOI: 10.1016/J.Jpba.2017.06.013 |
0.342 |
|
| 2017 |
Herbrink M, Nuijen B, Schellens JHM, Beijnen JH. High-Tech Drugs in Creaky Formulations. Pharmaceutical Research. PMID 28560695 DOI: 10.1007/S11095-017-2185-4 |
0.315 |
|
| 2017 |
Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, de Vries N, Rosing H, van Werkhoven E, de Boer A, Beijnen JH, Mandigers CMPW, Soesan M, Cats A, Schellens JHM. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. British Journal of Cancer. PMID 28427087 DOI: 10.1038/Bjc.2017.94 |
0.31 |
|
| 2017 |
van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Lucas L, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH. Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Investigational New Drugs. PMID 28303528 DOI: 10.1007/S10637-017-0451-2 |
0.558 |
|
| 2017 |
Verheijen RB, Beijnen JH, Schellens JH, Huitema AD, Steeghs N. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. Clinical Pharmacokinetics. PMID 28185218 DOI: 10.1007/S40262-017-0510-Z |
0.747 |
|
| 2017 |
Nijenhuis CM, Lucas L, Rosing H, Huitema AD, Mergui-Roelvink M, Jamieson GC, Fox JA, Mould DR, Schellens JH, Beijnen JH. Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II. Investigational New Drugs. PMID 28138829 DOI: 10.1007/S10637-017-0428-1 |
0.565 |
|
| 2017 |
van Andel L, Fudio S, Rosing H, Munt S, Miguel-Lillo B, González I, Tibben MM, de Vries N, de Vries Schultink AH, Schellens JH, Beijnen JH. Pharmacokinetics and excretion of (14)C-Plitidepsin in patients with advanced cancer. Investigational New Drugs. PMID 28111728 DOI: 10.1007/S10637-017-0432-5 |
0.54 |
|
| 2017 |
Sawicki E, Schellens JH, Beijnen JH, Nuijen B. Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies. Drug Development and Industrial Pharmacy. 43: 584-594. PMID 28010129 DOI: 10.1080/03639045.2016.1274901 |
0.47 |
|
| 2017 |
Verheijen RB, van Duijl TT, van den Heuvel MM, Beijnen JH, Schellens JH, van den Broek D, Steeghs N, Huitema A. Monitoring of circulating tumor DNA in non-small cell lung cancer patients treated with EGFR-inhibitors. Journal of Clinical Oncology. 35: 11535-11535. DOI: 10.1200/Jco.2017.35.15_Suppl.11535 |
0.479 |
|
| 2017 |
Hoppe Sv, Rood G, Wagenaar E, Sparidans R, Beijnen J, Schinkel A. Abstract 5218: Breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1) transport ibrutinib and may restrict its oral availability and brain accumulation, whereas CYP3A4 limits ibrutinib oral availability Cancer Research. 77: 5218-5218. DOI: 10.1158/1538-7445.Am2017-5218 |
0.324 |
|
| 2017 |
van Bussel M, Pluim D, Milojkovic-Kerklaan B, van den Broek D, Beijnen J, Boogerd W, Schellens J, Rhun EL, Brandsma D. CMET-12. TUMOR CELL DETECTION BY IMMUNOFLOW CYTOMETRY AND BRAF MUTATION ANALYSIS IN CEREBROSPINAL FLUID OF MELANOMA PATIENTS WITH SUSPECTED LEPTOMENINGEAL METASTASES Neuro-Oncology. 19: vi41-vi41. DOI: 10.1093/Neuonc/Nox168.161 |
0.442 |
|
| 2017 |
Zhang Z, Kansra V, van Andel L, Tibben M, Rosing H, Lu S, Agarwal S, Hughes L, Schellens J, Beijnen J. Characterization of Absorption, Metabolism, and Elimination of Niraparib, an Investigational Poly (ADP-Ribose) Polymerase Inhibitor, in Cancer Patients Clinical Therapeutics. 39: e7-e8. DOI: 10.1016/J.Clinthera.2017.05.025 |
0.303 |
|
| 2017 |
Herbrink M, Schellens J, Beijnen J, Nuijen B. Thermal study of pazopanib hydrochloride Journal of Thermal Analysis and Calorimetry. 130: 1491-1499. DOI: 10.1007/S10973-017-6286-4 |
0.454 |
|
| 2016 |
Sawicki E, Hillebrand MJ, Rosing H, Schellens JHM, Nuijen B, Beijnen JH. Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar. Journal of Pharmaceutical Analysis. 6: 268-275. PMID 29403992 DOI: 10.1016/J.Jpha.2016.04.005 |
0.328 |
|
| 2016 |
de Krou S, Rosing H, Nuijen B, Schellens JH, Beijnen JH. Fast and adequate liquid chromatography-tandem mass spectrometric determination of Z-endoxifen serum levels for therapeutic drug monitoring. Therapeutic Drug Monitoring. PMID 28045782 DOI: 10.1097/Ftd.0000000000000372 |
0.529 |
|
| 2016 |
de Vries Schultink AH, Alexi X, van Werkhoven E, Madlensky L, Natarajan L, Flatt SW, Zwart W, Linn SC, Parker BA, Wu AH, Pierce JP, Huitema AD, Beijnen JH. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome. Breast Cancer Research and Treatment. PMID 28005246 DOI: 10.1007/S10549-016-4083-6 |
0.313 |
|
| 2016 |
Leijen S, van Geel RM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, Pluim D, van Werkhoven E, Rose S, Lee MA, Freshwater T, Beijnen JH, Schellens JH. Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4354-4361. PMID 27998224 DOI: 10.1200/Jco.2016.67.5942 |
0.509 |
|
| 2016 |
van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Rosing H, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1040: 14-21. PMID 27898364 DOI: 10.1016/J.Jchromb.2016.11.020 |
0.528 |
|
| 2016 |
Sawicki E, Verheijen RB, Huitema AD, van Tellingen O, Schellens JH, Nuijen B, Beijnen JH, Steeghs N. Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar. Drug Delivery and Translational Research. PMID 27864786 DOI: 10.1007/S13346-016-0346-3 |
0.759 |
|
| 2016 |
Sawicki E, Schellens JH, Beijnen JH, Nuijen B. Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique. Cancer Treatment Reviews. 50: 247-263. PMID 27776286 DOI: 10.1016/J.Ctrv.2016.09.012 |
0.513 |
|
| 2016 |
Herbrink M, de Vries N, Rosing H, Huitema AD, Nuijen B, Schellens JH, Beijnen JH. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry. Therapeutic Drug Monitoring. 38: 649-656. PMID 27749781 DOI: 10.1097/Ftd.0000000000000349 |
0.732 |
|
| 2016 |
Sparidans RW, Rosing H, Rood JJ, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1033: 390-398. PMID 27639128 DOI: 10.1016/J.Jchromb.2016.09.012 |
0.496 |
|
| 2016 |
Meulendijks D, Cats A, Beijnen JH, Schellens JH. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice? Cancer Treatment Reviews. 50: 23-34. PMID 27589829 DOI: 10.1016/J.Ctrv.2016.08.002 |
0.506 |
|
| 2016 |
Herbrink M, Schellens JHM, Beijnen JH, Nuijen B. Inherent formulation issues of kinase inhibitors. Journal of Controlled Release. 239: 118-127. PMID 27578098 DOI: 10.1016/J.Jconrel.2016.08.036 |
0.316 |
|
| 2016 |
Lin F, de Gooijer MC, Hanekamp D, Chandrasekaran G, Buil L, Thota N, Sparidans RW, Beijnen JH, Wurdinger T, van Tellingen O. PI3K-mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27553832 DOI: 10.1158/1078-0432.Ccr-16-1276 |
0.303 |
|
| 2016 |
Meulendijks D, Henricks LM, van Kuilenburg AB, Jacobs BA, Aliev A, Rozeman L, Meijer J, Beijnen JH, de Graaf H, Cats A, Schellens JH. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. Cancer Chemotherapy and Pharmacology. PMID 27544765 DOI: 10.1007/S00280-016-3137-0 |
0.447 |
|
| 2016 |
Yu H, van Erp N, Bins S, Mathijssen RH, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients. Clinical Pharmacokinetics. PMID 27534647 DOI: 10.1007/S40262-016-0443-Y |
0.743 |
|
| 2016 |
Sawicki E, Beijnen JH, Schellens JH, Nuijen B. Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel. International Journal of Pharmaceutics. PMID 27480397 DOI: 10.1016/J.Ijpharm.2016.07.068 |
0.488 |
|
| 2016 |
Verheijen RB, Bins S, Mathijssen RH, Lolkema M, van Doorn L, Schellens JH, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N. Individualized pazopanib dosing: a prospective feasibility study in cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27470967 DOI: 10.1158/1078-0432.Ccr-16-1255 |
0.754 |
|
| 2016 |
Rood JJ, van Bussel MT, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1031: 80-85. PMID 27469903 DOI: 10.1016/J.Jchromb.2016.07.037 |
0.514 |
|
| 2016 |
Rood JJ, Schellens JH, Beijnen JH, Sparidans RW. Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. Journal of Pharmaceutical and Biomedical Analysis. PMID 27460293 DOI: 10.1016/J.Jpba.2016.06.037 |
0.5 |
|
| 2016 |
van Brummelen EM, Ros W, Wolbink G, Beijnen JH, Schellens JH. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. The Oncologist. PMID 27440064 DOI: 10.1634/Theoncologist.2016-0061 |
0.492 |
|
| 2016 |
Nijenhuis CM, Huitema AD, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients. Journal of Clinical Pharmacology. PMID 27365214 DOI: 10.1002/Jcph.788 |
0.517 |
|
| 2016 |
Nijenhuis CM, Lucas L, Rosing H, Jamieson G, Fox JA, Schellens JH, Beijnen JH. Quantification of vosaroxin and its metabolites N-desmethylvosaroxin and O-desmethylvosaroxin in human plasma and urine using high-performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1027: 1-10. PMID 27236532 DOI: 10.1016/J.Jchromb.2016.05.016 |
0.512 |
|
| 2016 |
Nijenhuis CM, Hellriegel E, Beijnen JH, Hershock D, Huitema AD, Lucas L, Mergui-Roelvink M, Munteanu M, Rabinovich-Guilatt L, Robertson P, Rosing H, Spiegelstein O, Schellens JH. Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors. Investigational New Drugs. PMID 27221729 DOI: 10.1007/S10637-016-0360-9 |
0.767 |
|
| 2016 |
Nijenhuis CM, Schellens JH, Beijnen JH. Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review. Drug Metabolism Reviews. 48: 266-80. PMID 27186889 DOI: 10.1080/03602532.2016.1181081 |
0.467 |
|
| 2016 |
Sparidans RW, Kort A, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1023: 24-29. PMID 27179188 DOI: 10.1016/J.Jchromb.2016.04.049 |
0.517 |
|
| 2016 |
Jacobs BA, Rosing H, de Vries N, Meulendijks D, Henricks LM, Schellens JH, Beijnen JH. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 126: 75-82. PMID 27179185 DOI: 10.1016/J.Jpba.2016.04.039 |
0.492 |
|
| 2016 |
Deenen MJ, Cats A, Severens JL, Beijnen JH, Schellens JH. Reply to T. Magnes et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27161961 DOI: 10.1200/Jco.2016.67.4374 |
0.373 |
|
| 2016 |
Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krähenbühl MD, van Geel RM, de Vries N, Rosing H, Meulendijks D, Burylo AM, Cats A, Beijnen JH, Huitema AD, Schellens JH. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. British Journal of Clinical Pharmacology. PMID 27161955 DOI: 10.1111/Bcp.13007 |
0.767 |
|
| 2016 |
Jacobs BA, Meulenaar J, Rosing H, Pluim D, Tibben MM, de Vries N, Nuijen B, Huitema AD, Beijnen JH, Schellens JH, Marchetti S. A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine. Cancer Chemotherapy and Pharmacology. PMID 27103124 DOI: 10.1007/S00280-016-3035-5 |
0.72 |
|
| 2016 |
Dubbelman AC, Tibben M, Rosing H, Gebretensae A, Nan L, Gorman SH, Robertson P, Schellens JH, Beijnen JH. Corrigendum to "Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine" [J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 893-894 (2012) 92-100]. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1020: 168-169. PMID 27063483 DOI: 10.1016/J.Jchromb.2016.03.016 |
0.458 |
|
| 2016 |
Nijenhuis CM, Haverkate H, Rosing H, Schellens JH, Beijnen JH. Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 125: 270-9. PMID 27058232 DOI: 10.1016/J.Jpba.2016.03.049 |
0.53 |
|
| 2016 |
Dubbelman AC, Nijenhuis CM, Jansen RS, Rosing H, Mizuo H, Kawaguchi S, Critchley D, Shumaker R, Schellens JH, Beijnen JH. Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison. Investigational New Drugs. PMID 27018262 DOI: 10.1007/S10637-016-0342-Y |
0.514 |
|
| 2016 |
Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, Beeker A, Portielje JE, Goey SH, de Jong RS, Vanhoutvin SA, Kuiper M, Sikorska K, Pluim D, Beijnen JH, et al. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. Cancer. PMID 26970343 DOI: 10.1002/Cncr.29864 |
0.466 |
|
| 2016 |
van Brummelen EM, Huitema AD, van Werkhoven E, Beijnen JH, Schellens JH. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years. Journal of Pharmacokinetics and Pharmacodynamics. PMID 26960536 DOI: 10.1007/S10928-016-9466-0 |
0.495 |
|
| 2016 |
Nijenhuis CM, Huitema AD, Marchetti S, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH. The use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients. Journal of Clinical Pharmacology. PMID 26918324 DOI: 10.1002/Jcph.728 |
0.737 |
|
| 2016 |
de Vries Schultink AH, Suleiman AA, Schellens JH, Beijnen JH, Huitema AD. Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment. European Journal of Clinical Pharmacology. PMID 26915815 DOI: 10.1007/S00228-016-2030-4 |
0.527 |
|
| 2016 |
van Geel RM, Hendrikx JJ, Vahl JE, van Leerdam ME, van den Broek D, Huitema AD, Beijnen JH, Schellens JH, Burgers SA. Crizotinib-induced fatal fulminant liver failure. Lung Cancer (Amsterdam, Netherlands). 93: 17-9. PMID 26898609 DOI: 10.1016/J.Lungcan.2015.12.010 |
0.705 |
|
| 2016 |
Sparidans RW, van Hoppe S, Rood JJ, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1012: 118-123. PMID 26826475 DOI: 10.1016/J.Jchromb.2016.01.025 |
0.509 |
|
| 2016 |
Meulendijks D, Henricks LM, Amstutz U, Froehlich TK, Largiadèr CR, Beijnen JH, de Boer A, Deenen MJ, Cats A, Schellens JH. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity. International Journal of Cancer. Journal International Du Cancer. PMID 26804235 DOI: 10.1002/Ijc.30014 |
0.445 |
|
| 2016 |
Kip AE, Rosing H, Hillebrand MJ, Blesson S, Mengesha B, Diro E, Hailu A, Schellens JH, Beijnen JH, Dorlo TP. Validation and clinical evaluation of a novel method to measure miltefosine in leishmaniasis patients using dried blood spot sample collection. Antimicrobial Agents and Chemotherapy. PMID 26787691 DOI: 10.1128/Aac.02976-15 |
0.479 |
|
| 2016 |
Meulendijks D, van Hasselt JG, Huitema AD, van Tinteren H, Deenen MJ, Beijnen JH, Cats A, Schellens JH. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. European Journal of Cancer (Oxford, England : 1990). 54: 120-130. PMID 26761784 DOI: 10.1016/J.Ejca.2015.10.013 |
0.783 |
|
| 2016 |
Crombag MR, Joerger M, Thürlimann B, Schellens JH, Beijnen JH, Huitema AD. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers. 8. PMID 26729170 DOI: 10.3390/Cancers8010006 |
0.743 |
|
| 2016 |
de Weger V, Stuurman F, Mergui-Roelvink M, Nuijen B, Huitema A, Beijnen J, Schellens J, Marchetti S. A phase I dose-escalation trial of bi-daily (BID) weekly oral docetaxel as ModraDoc006 in combination with ritonavir Annals of Oncology. 27: vi127. DOI: 10.1093/Annonc/Mdw368.42 |
0.333 |
|
| 2015 |
Derissen EJ, Jacobs BA, Huitema AD, Rosing H, Schellens JH, Beijnen JH. Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. British Journal of Clinical Pharmacology. PMID 26718616 DOI: 10.1111/Bcp.12877 |
0.727 |
|
| 2015 |
Verheijen RB, Bins S, Thijssen B, Rosing H, Nan L, Schellens JH, Mathijssen RH, Lolkema MP, Beijnen JH, Steeghs N, Huitema AD. Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS. Bioanalysis. PMID 26652864 DOI: 10.4155/Bio.15.235 |
0.735 |
|
| 2015 |
Meulendijks D, Beerepoot LV, Boot H, de Groot JW, Los M, Boers JE, Vanhoutvin SA, Polee MB, Beeker A, Portielje JE, de Jong RS, Goey SH, Kuiper M, Sikorska K, Beijnen JH, et al. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. Investigational New Drugs. PMID 26643663 DOI: 10.1007/S10637-015-0309-4 |
0.479 |
|
| 2015 |
van Geel RM, Beijnen JH, Bernards R, Schellens JH. Treatment Individualization in Colorectal Cancer. Current Colorectal Cancer Reports. 11: 335-344. PMID 26617477 DOI: 10.1007/S11888-015-0288-Z |
0.466 |
|
| 2015 |
Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, ... ... Beijnen JH, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. The Lancet. Oncology. PMID 26603945 DOI: 10.1016/S1470-2045(15)00286-7 |
0.414 |
|
| 2015 |
Yu H, Hendrikx JJ, Rottenberg S, Schellens JH, Beijnen JH, Huitema AD. Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer. The Aaps Journal. PMID 26603889 DOI: 10.1208/S12248-015-9838-1 |
0.736 |
|
| 2015 |
Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H, Mandigers CM, Soesan M, Beijnen JH, Schellens JH. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26573078 DOI: 10.1200/Jco.2015.63.1325 |
0.452 |
|
| 2015 |
Milojkovic Kerklaan B, Pluim D, Bol M, Hofland I, Westerga J, van Tinteren H, Beijnen JH, Boogerd W, Schellens JH, Brandsma D. EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors. Neuro-Oncology. PMID 26566655 DOI: 10.1093/Neuonc/Nov273 |
0.427 |
|
| 2015 |
Henricks LM, Schellens JH, Huitema AD, Beijnen JH. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treatment Reviews. PMID 26547132 DOI: 10.1016/J.Ctrv.2015.10.008 |
0.721 |
|
| 2015 |
Rood JJ, van Hoppe S, Schinkel AH, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis. 118: 123-131. PMID 26540627 DOI: 10.1016/J.Jpba.2015.10.033 |
0.506 |
|
| 2015 |
Keusters WR, Frederix GW, de Weger VA, Beijnen JH, Hövels AM, Schellens JH. Decrease of Patient Costs in the Netherlands: a Cost of Illness Study in Metastatic Non Small Cell Lung Cancer (Nsclc). Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: A446. PMID 26532512 DOI: 10.1016/J.Jval.2015.09.1113 |
0.424 |
|
| 2015 |
Deenen MJ, Meulendijks D, Boot H, Legdeur MJ, Beijnen JH, Schellens JH, Cats A. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. Cancer Chemotherapy and Pharmacology. PMID 26499900 DOI: 10.1007/S00280-015-2872-Y |
0.479 |
|
| 2015 |
Milojkovic Kerklaan B, van Tellingen O, Huitema AD, Beijnen JH, Boogerd W, Schellens JH, Brandsma D. Strategies to target drugs to gliomas and CNS metastases of solid tumors. Journal of Neurology. PMID 26477024 DOI: 10.1007/S00415-015-7919-9 |
0.447 |
|
| 2015 |
van der Noll R, Smit WM, Wymenga AN, Boss DS, Grob M, Huitema AD, Rosing H, Tibben MM, Keessen M, Rehorst H, Beijnen JH, Schellens JH. Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. Investigational New Drugs. PMID 26362459 DOI: 10.1007/S10637-015-0281-Z |
0.54 |
|
| 2015 |
Nijenhuis CM, Lucas L, Rosing H, Schellens JH, Beijnen JH, Gorman SH, Burke SM, Campbell DA, Chapple MW, Yousey TH, Mulvana DE. Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'‑des-methyl and cephalotaxine metabolites in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1002: 152-9. PMID 26319804 DOI: 10.1016/J.Jchromb.2015.08.015 |
0.516 |
|
| 2015 |
Tang SC, Kort A, Cheung KL, Rosing H, Fukami T, Durmus S, Wagenaar E, Hendrikx JJ, Nakajima M, van Vlijmen BJ, Beijnen JH, Schinkel AH. P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice. Molecular Pharmaceutics. PMID 26317243 DOI: 10.1021/Acs.Molpharmaceut.5B00470 |
0.337 |
|
| 2015 |
van Hasselt J, Gupta A, Hussein Z, Beijnen JH, Schellens J, Huitema A. Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin. Cpt: Pharmacometrics & Systems Pharmacology. 4: 386-95. PMID 26312162 DOI: 10.1002/psp4.49 |
0.735 |
|
| 2015 |
van Hasselt J, Gupta A, Hussein Z, Beijnen JH, Schellens J, Huitema A. Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin. Cpt: Pharmacometrics & Systems Pharmacology. 4: 374-85. PMID 26312161 DOI: 10.1002/psp4.48 |
0.747 |
|
| 2015 |
Hendrikx JJ, Lagas JS, Song JY, Rosing H, Schellens JH, Beijnen JH, Rottenberg S, Schinkel AH. Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model. International Journal of Cancer. Journal International Du Cancer. PMID 26297509 DOI: 10.1002/Ijc.29812 |
0.496 |
|
| 2015 |
Meulendijks D, Jacobs BA, Aliev A, Pluim D, van Werkhoven E, Deenen MJ, Beijnen JH, Cats A, Schellens JH. Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G>C Substitution in the First 28-bp tandem repeat of the thymidylate synthase 2R Allele. International Journal of Cancer. Journal International Du Cancer. PMID 26189437 DOI: 10.1002/Ijc.29694 |
0.466 |
|
| 2015 |
van der Noll R, Marchetti S, Steeghs N, Beijnen JH, Mergui-Roelvink MW, Harms E, Rehorst H, Sonke GS, Schellens JH. Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. British Journal of Cancer. 113: 396-402. PMID 26180927 DOI: 10.1038/Bjc.2015.256 |
0.465 |
|
| 2015 |
Kip AE, Rosing H, Hillebrand MJ, Castro MM, Gomez MA, Schellens JH, Beijnen JH, Dorlo TP. Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 998: 57-62. PMID 26160472 DOI: 10.1016/J.Jchromb.2015.06.017 |
0.526 |
|
| 2015 |
Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JH, Huitema AD. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacology Research & Perspectives. 3: e00131. PMID 26038706 DOI: 10.1002/Prp2.131 |
0.721 |
|
| 2015 |
Jager NG, Rosing H, Linn SC, Schellens JH, Beijnen JH. Dried blood spot self-sampling at home for the individualization of tamoxifen treatment: a feasibility study. Therapeutic Drug Monitoring. PMID 26035041 DOI: 10.1097/Ftd.0000000000000224 |
0.414 |
|
| 2015 |
Jager NG, Linn SC, Schellens JH, Beijnen JH. Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective. Clinical Breast Cancer. PMID 25997856 DOI: 10.1016/J.Clbc.2015.04.005 |
0.525 |
|
| 2015 |
de Vries Schultink AH, Zwart W, Linn SC, Beijnen JH, Huitema AD. Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clinical Pharmacokinetics. 54: 797-810. PMID 25940823 DOI: 10.1007/S40262-015-0273-3 |
0.704 |
|
| 2015 |
van Hasselt JG, Allegaert K, van Calsteren K, Beijnen JH, Schellens JH, Huitema AD. Corrigendum to "Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy". Biomed Research International. 2015: 124035. PMID 25922829 DOI: 10.1155/2015/124035 |
0.78 |
|
| 2015 |
Meulendijks D, Tomasoa NB, Dewit L, Smits PH, Bakker R, van Velthuysen ML, Rosenberg EH, Beijnen JH, Schellens JH, Cats A. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. British Journal of Cancer. 112: 1358-66. PMID 25871546 DOI: 10.1038/Bjc.2015.20 |
0.403 |
|
| 2015 |
Pluim D, Jacobs BA, Deenen MJ, Ruijter AE, van Geel RM, Burylo AM, Meulendijks D, Beijnen JH, Schellens JH. Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Bioanalysis. 7: 519-29. PMID 25826134 DOI: 10.4155/Bio.14.304 |
0.448 |
|
| 2015 |
Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treatment Reviews. 41: 412-422. PMID 25818541 DOI: 10.1016/J.Ctrv.2015.03.005 |
0.505 |
|
| 2015 |
Derissen EJ, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH. Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil. Journal of Pharmaceutical and Biomedical Analysis. 110: 58-66. PMID 25804433 DOI: 10.1016/J.Jpba.2015.02.051 |
0.508 |
|
| 2015 |
Vogel CJ, Smit MA, Maddalo G, Possik PA, Sparidans RW, van der Burg SH, Verdegaal EM, Heck AJ, Samatar AA, Beijnen JH, Altelaar AF, Peeper DS. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK. Pigment Cell & Melanoma Research. 28: 307-17. PMID 25728708 DOI: 10.1111/Pcmr.12364 |
0.311 |
|
| 2015 |
Lankheet NA, Schaake EE, Burgers SA, van Pel R, Beijnen JH, Huitema AD, Klomp H. Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy. Clinical Lung Cancer. 16: 320-4. PMID 25682545 DOI: 10.1016/J.Cllc.2014.12.012 |
0.675 |
|
| 2015 |
Joerger M, Huitema AD, Boot H, Cats A, Doodeman VD, Smits PH, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny TD, Beijnen JH, Schellens JH. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemotherapy and Pharmacology. 75: 763-72. PMID 25677447 DOI: 10.1007/S00280-015-2698-7 |
0.487 |
|
| 2015 |
Devriese LA, Witteveen PE, Mergui-Roelvink M, Smith DA, Lewis LD, Mendelson DS, Bang YJ, Chung HC, Dar MM, Huitema AD, Beijnen JH, Voest EE, Schellens JH. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. British Journal of Clinical Pharmacology. PMID 25677219 DOI: 10.1111/Bcp.12606 |
0.735 |
|
| 2015 |
Dolman ME, Westerhout EM, Hamdi M, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate. Journal of Pharmaceutical and Biomedical Analysis. 107: 403-8. PMID 25659532 DOI: 10.1016/J.Jpba.2015.01.026 |
0.516 |
|
| 2015 |
Meulendijks D, Khan S, Koks CH, Huitema AD, Schellens JH, Beijnen JH. Baclofen overdose treated with continuous venovenous hemofiltration. European Journal of Clinical Pharmacology. 71: 357-61. PMID 25567218 DOI: 10.1007/S00228-014-1802-Y |
0.714 |
|
| 2015 |
Yu H, Steeghs N, Kloth JS, de Wit D, van Hasselt JG, van Erp NP, Beijnen JH, Schellens JH, Mathijssen RH, Huitema AD. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. British Journal of Clinical Pharmacology. 79: 809-19. PMID 25393890 DOI: 10.1111/Bcp.12550 |
0.788 |
|
| 2015 |
Dubbelman AC, Rosing H, Nijenhuis C, Huitema AD, Mergui-Roelvink M, Gupta A, Verbel D, Thompson G, Shumaker R, Schellens JH, Beijnen JH. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. Investigational New Drugs. 33: 233-40. PMID 25377392 DOI: 10.1007/S10637-014-0181-7 |
0.76 |
|
| 2015 |
Kip AE, Balasegaram M, Beijnen JH, Schellens JH, de Vries PJ, Dorlo TP. Systematic review of biomarkers to monitor therapeutic response in leishmaniasis. Antimicrobial Agents and Chemotherapy. 59: 1-14. PMID 25367913 DOI: 10.1128/Aac.04298-14 |
0.469 |
|
| 2015 |
Leijen S, Burgers SA, Baas P, Pluim D, Tibben M, van Werkhoven E, Alessio E, Sava G, Beijnen JH, Schellens JH. Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Investigational New Drugs. 33: 201-14. PMID 25344453 DOI: 10.1007/S10637-014-0179-1 |
0.495 |
|
| 2015 |
Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharmaceutical Research. 32: 37-46. PMID 24962512 DOI: 10.1007/S11095-014-1442-Z |
0.314 |
|
| 2015 |
Iusuf D, Hendrikx JJMA, van Esch A, van de Steeg E, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel International Journal of Cancer. Journal International Du Cancer. 136: 225-233. PMID 24825069 DOI: 10.1002/Ijc.28970 |
0.314 |
|
| 2015 |
Janssens T, Brouwers EE, de Vos JP, de Vries N, Schellens JH, Beijnen JH. Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs. Veterinary and Comparative Oncology. 13: 124-32. PMID 23714139 DOI: 10.1111/Vco.12025 |
0.488 |
|
| 2015 |
Leijen S, van Geel R, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, Pluim D, van Werkhoven ED, Rose S, Lee MA, Beijnen JH, Schellens JHM. Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (<3 months) to standard first line therapy. Journal of Clinical Oncology. 33: 2507-2507. DOI: 10.1200/Jco.2015.33.15_Suppl.2507 |
0.324 |
|
| 2015 |
Van Hasselt JGC, Gupta A, Hussein Z, Beijnen JH, Schellens JHM, Huitema ADR. Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated with Eribulin Cpt: Pharmacometrics and Systems Pharmacology. 4: 386-395. DOI: 10.1002/psp4.49 |
0.682 |
|
| 2015 |
Van Hasselt JGC, Gupta A, Hussein Z, Beijnen JH, Schellens JHM, Huitema ADR. Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment with Eribulin Cpt: Pharmacometrics and Systems Pharmacology. 4: 374-385. DOI: 10.1002/psp4.48 |
0.687 |
|
| 2014 |
Joerger M, Huitema AD, Boot H, Cats A, Doodeman V, Smits P, Vainchtein L, Rosing H, Meijerman I, Zueger M, Cerny TT, Beijnen JH, Schellens J. 1577PGERMLINE TYMS GENOTYPE IS HIGHLY PREDICTIVE IN PATIENTS WITH ADVANCED COLORECTAL AND GASTROESOPHAGEAL CANCER INDEPENDENT OF FLUOROPYRIMIDINE PHARMACOLOGY: RESULTS FROM TWO PROSPECTIVE TRANSLATIONAL STUDIES. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv548. PMID 28172174 DOI: 10.1093/Annonc/Mdu358.8 |
0.461 |
|
| 2014 |
Nijenhuis CM, Rosing H, Schellens JH, Beijnen JH. Quantifying vemurafenib in dried blood spots using high-performance LC-MS/MS. Bioanalysis. 6: 3215-24. PMID 25529888 DOI: 10.4155/Bio.14.171 |
0.448 |
|
| 2014 |
Jager NG, Rosing H, Schellens JH, Beijnen JH. Determination of tamoxifen and endoxifen in dried blood spots using LC-MS/MS and the effect of coated DBS cards on recovery and matrix effects. Bioanalysis. 6: 2999-3009. PMID 25496254 DOI: 10.4155/Bio.14.157 |
0.446 |
|
| 2014 |
Jager NG, Rosing H, Schellens JH, Beijnen JH. Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review. Bioanalysis. 6: 2481-514. PMID 25384597 DOI: 10.4155/Bio.14.185 |
0.458 |
|
| 2014 |
Crombag MR, de Vries Schultink AH, Schellens JH, Beijnen JH, Huitema AD. Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study. Drugs & Aging. 31: 737-47. PMID 25216600 DOI: 10.1007/S40266-014-0207-Z |
0.715 |
|
| 2014 |
van Hasselt JG, van Eijkelenburg NK, Beijnen JH, Schellens JH, Huitema AD. Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation. Pediatric Blood & Cancer. 61: 2223-9. PMID 25175364 DOI: 10.1002/Pbc.25198 |
0.784 |
|
| 2014 |
Meulendijks D, Dewit L, Tomasoa NB, van Tinteren H, Beijnen JH, Schellens JH, Cats A. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. British Journal of Cancer. 111: 1726-33. PMID 25167226 DOI: 10.1038/Bjc.2014.467 |
0.449 |
|
| 2014 |
Opdam FL, Huitema AD, Beijnen JH, Schellens JH. [Hyperglycaemia during treatment with everolimus]. Nederlands Tijdschrift Voor Geneeskunde. 158: A7544. PMID 25115206 |
0.701 |
|
| 2014 |
Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. "Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183". Investigational New Drugs. 32: 1083-95. PMID 25078948 DOI: 10.1007/S10637-014-0143-0 |
0.51 |
|
| 2014 |
Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Levêque D, Veal G, Astier A. Review of therapeutic drug monitoring of anticancer drugs part two - Targeted therapies European Journal of Cancer. 50: 2020-2036. PMID 24928190 DOI: 10.1016/J.Ejca.2014.04.015 |
0.392 |
|
| 2014 |
Paci A, Veal G, Bardin C, Levêque D, Widmer N, Beijnen J, Astier A, Chatelut E. Review of therapeutic drug monitoring of anticancer drugs part 1 - Cytotoxics European Journal of Cancer. 50: 2010-2019. PMID 24889915 DOI: 10.1016/J.Ejca.2014.04.014 |
0.415 |
|
| 2014 |
Bardin C, Veal G, Paci A, Chatelut E, Astier A, Levêque D, Widmer N, Beijnen J. Therapeutic drug monitoring in cancer - Are we missing a trick? European Journal of Cancer. 50: 2005-2009. PMID 24878063 DOI: 10.1016/J.Ejca.2014.04.013 |
0.398 |
|
| 2014 |
Jager NG, Rosing H, Schellens JH, Beijnen JH, Linn SC. Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen. Breast Cancer Research and Treatment. 146: 137-44. PMID 24859000 DOI: 10.1007/S10549-014-2999-2 |
0.458 |
|
| 2014 |
Hendrikx JJ, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Quantification of taxanes in biological matrices: a review of bioanalytical assays and recommendations for development of new assays. Bioanalysis. 6: 993-1010. PMID 24806907 DOI: 10.4155/Bio.14.48 |
0.485 |
|
| 2014 |
van Hasselt JG, Schellens JH, Beijnen JH, Huitema AD. Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error. Investigational New Drugs. 32: 913-27. PMID 24788562 DOI: 10.1007/S10637-014-0103-8 |
0.783 |
|
| 2014 |
Hendrikx JJ, Lagas JS, Wagenaar E, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. British Journal of Cancer. 110: 2669-76. PMID 24781280 DOI: 10.1038/Bjc.2014.222 |
0.506 |
|
| 2014 |
Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, Schellens JH, Voest EE, Sleijfer S, de Jonge MJ, Haanen JB, Beijnen JH, Huitema AD, Steeghs N. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. British Journal of Cancer. 110: 2441-9. PMID 24736581 DOI: 10.1038/Bjc.2014.194 |
0.54 |
|
| 2014 |
Mooiman KD, Goey AK, Huijbregts TJ, Maas-Bakker RF, Beijnen JH, Schellens JH, Meijerman I. The in-vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity. The Journal of Pharmacy and Pharmacology. 66: 1339-46. PMID 24730468 DOI: 10.1111/Jphp.12259 |
0.512 |
|
| 2014 |
Hendrikx JJ, Lagas JS, Daling R, Hooijberg JH, Schellens JH, Beijnen JH, Brandjes DP, Huitema AD. Severe lactic acidosis in a diabetic patient after ethanol abuse and floor cleaner intake. Basic & Clinical Pharmacology & Toxicology. 115: 472-5. PMID 24717115 DOI: 10.1111/Bcpt.12251 |
0.701 |
|
| 2014 |
van Hasselt JG, van Calsteren K, Heyns L, Han S, Mhallem Gziri M, Schellens JH, Beijnen JH, Huitema AD, Amant F. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 2059-65. PMID 24713311 DOI: 10.1093/Annonc/Mdu140 |
0.769 |
|
| 2014 |
ter Heine R, Binkhorst L, de Graan AJ, de Bruijn P, Beijnen JH, Mathijssen RH, Huitema AD. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. British Journal of Clinical Pharmacology. 78: 572-86. PMID 24697814 DOI: 10.1111/Bcp.12388 |
0.689 |
|
| 2014 |
van Hasselt JG, Allegaert K, van Calsteren K, Beijnen JH, Schellens JH, Huitema AD. Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. Biomed Research International. 2014: 897216. PMID 24672799 DOI: 10.1155/2014/897216 |
0.782 |
|
| 2014 |
Goey AK, Beijnen JH, Schellens JH. Herb-drug interactions in oncology. Clinical Pharmacology and Therapeutics. 95: 354-5. PMID 24646483 DOI: 10.1038/Clpt.2014.18 |
0.452 |
|
| 2014 |
de Weger VA, Beijnen JH, Schellens JH. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review. Anti-Cancer Drugs. 25: 488-94. PMID 24637579 DOI: 10.1097/Cad.0000000000000093 |
0.524 |
|
| 2014 |
Luethi D, Durmus S, Schinkel AH, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. Biomedical Chromatography : Bmc. 28: 1366-70. PMID 24619951 DOI: 10.1002/Bmc.3176 |
0.528 |
|
| 2014 |
Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, Huitema AD. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clinical Pharmacokinetics. 53: 305-25. PMID 24566736 DOI: 10.1007/S40262-014-0137-2 |
0.752 |
|
| 2014 |
Dolman ME, den Hartog IJ, Molenaar JJ, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis. 92: 144-8. PMID 24518133 DOI: 10.1016/J.Jpba.2014.01.011 |
0.51 |
|
| 2014 |
Dorlo TPC, Rijal S, Ostyn B, De Vries PJ, Singh R, Bhattarai N, Uranw S, Dujardin JC, Boelaert M, Beijnen JH, Huitema ADR. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure Journal of Infectious Diseases. 210: 146-153. PMID 24443541 DOI: 10.1093/Infdis/Jiu039 |
0.334 |
|
| 2014 |
Mooiman KD, Maas-Bakker RF, Hendrikx JJ, Bank PC, Rosing H, Beijnen JH, Schellens JH, Meijerman I. The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-trifluoromethyl-coumarin, midazolam and docetaxel. The Journal of Pharmacy and Pharmacology. 66: 865-74. PMID 24392691 DOI: 10.1111/Jphp.12208 |
0.492 |
|
| 2014 |
Jager NG, Rosing H, Schellens JH, Linn SC, Beijnen JH. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. Breast Cancer Research and Treatment. 143: 477-83. PMID 24390246 DOI: 10.1007/S10549-013-2826-1 |
0.541 |
|
| 2014 |
Vlaming ML, Teunissen SF, van de Steeg E, van Esch A, Wagenaar E, Brunsveld L, de Greef TF, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites. Molecular Pharmacology. 85: 520-30. PMID 24334255 DOI: 10.1124/Mol.113.088823 |
0.456 |
|
| 2014 |
Derissen EJ, Hillebrand MJ, Rosing H, Otten HM, Laille E, Schellens JH, Beijnen JH. Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 90: 7-14. PMID 24317024 DOI: 10.1016/J.Jpba.2013.11.010 |
0.497 |
|
| 2014 |
Meulenaar J, Keizer RJ, Beijnen JH, Schellens JH, Huitema AD, Nuijen B. Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling. Journal of Pharmaceutical Sciences. 103: 478-84. PMID 24311366 DOI: 10.1002/Jps.23779 |
0.725 |
|
| 2014 |
Lankheet NA, Knapen LM, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Therapeutic Drug Monitoring. 36: 326-34. PMID 24305627 DOI: 10.1097/Ftd.0000000000000004 |
0.735 |
|
| 2014 |
Helgason HH, Koolen SL, Werkhoven Ev, Malingre MM, Kruijtzer CM, Huitema AD, Schot ME, Smit WM, Beijnen JH, Schellens JH. Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer. Current Clinical Pharmacology. 9: 139-47. PMID 24219005 DOI: 10.2174/1574884708666131111193403 |
0.733 |
|
| 2014 |
Nijenhuis CM, Rosing H, Schellens JH, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 88: 630-5. PMID 24216282 DOI: 10.1016/J.Jpba.2013.10.019 |
0.525 |
|
| 2014 |
Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. Journal of Pharmaceutical and Biomedical Analysis. 88: 626-9. PMID 24216281 DOI: 10.1016/J.Jpba.2013.10.016 |
0.512 |
|
| 2014 |
Joerger M, Huitema AD, Koeberle D, Rosing H, Beijnen JH, Hitz F, Cerny T, Schellens JH, Gillessen S. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemotherapy and Pharmacology. 73: 113-24. PMID 24166106 DOI: 10.1007/S00280-013-2327-2 |
0.541 |
|
| 2014 |
Dolman ME, den Hartog IJ, Molenaar JJ, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis. 88: 216-20. PMID 24080524 DOI: 10.1016/J.Jpba.2013.08.051 |
0.515 |
|
| 2014 |
Goey AK, Meijerman I, Rosing H, Marchetti S, Mergui-Roelvink M, Keessen M, Burgers JA, Beijnen JH, Schellens JH. The effect of St John's wort on the pharmacokinetics of docetaxel. Clinical Pharmacokinetics. 53: 103-10. PMID 24068654 DOI: 10.1007/S40262-013-0102-5 |
0.544 |
|
| 2014 |
Chuan Tang S, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. International Journal of Cancer. Journal International Du Cancer. 134: 1484-94. PMID 24037730 DOI: 10.1002/Ijc.28475 |
0.33 |
|
| 2014 |
Hendrikx JJ, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS/MS. Biomedical Chromatography : Bmc. 28: 302-10. PMID 23996474 DOI: 10.1002/Bmc.3021 |
0.535 |
|
| 2014 |
Verheijen R, Bins S, Gadellaa-van Hooijdonk C, Mathijssen R, Lolkema M, van Doorn L, Rotteveel-Buchholtz K, Schellens J, Beijnen J, Huitema A, Steeghs N. Individualized Pharmacokinetically-Guided Dosing of Pazopanib: a Feasibility Study in Cancer Patients Annals of Oncology. 25: iv162. DOI: 10.1093/Annonc/Mdu331.46 |
0.412 |
|
| 2013 |
Moes JJ, Stuurman FE, Hendrikx JJ, Marchetti S, Huitema AD, Beijnen JH, Schellens JH, Nuijen B. Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet. Drug Delivery and Translational Research. 3: 243-51. PMID 25788133 DOI: 10.1007/S13346-012-0127-6 |
0.765 |
|
| 2013 |
Jager NG, Koornstra RH, Vincent AD, van Schaik RH, Huitema AD, Korse TM, Schellens JH, Linn SC, Beijnen JH. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. Bmc Cancer. 13: 612. PMID 24373320 DOI: 10.1186/1471-2407-13-612 |
0.731 |
|
| 2013 |
Slingerland M, Guchelaar HJ, Rosing H, Scheulen ME, van Warmerdam LJC, Beijnen JH, Gelderblom H. Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer Clinical Therapeutics. 35: 1946-1954. PMID 24290734 DOI: 10.1016/J.Clinthera.2013.10.009 |
0.355 |
|
| 2013 |
Nijenhuis CM, Lucas L, Rosing H, Schellens JH, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 940: 121-5. PMID 24145016 DOI: 10.1016/J.Jchromb.2013.09.020 |
0.524 |
|
| 2013 |
Janssens T, Brouwers EE, de Vos JP, de Vries N, Schellens JH, Beijnen JH. Determination of platinum surface contamination in veterinary and human oncology centres using inductively coupled plasma mass spectrometry. Veterinary and Comparative Oncology. PMID 24034226 DOI: 10.1111/Vco.12049 |
0.491 |
|
| 2013 |
de Groot MH, van Campen JP, Moek MA, Tulner LR, Beijnen JH, Lamoth CJ. The effects of fall-risk-increasing drugs on postural control: a literature review. Drugs & Aging. 30: 901-20. PMID 24005984 DOI: 10.1007/S40266-013-0113-9 |
0.312 |
|
| 2013 |
Lankheet NA, Huitema AD, Mallo H, Adriaansz S, Haanen JB, Schellens JH, Beijnen JH, Blank CU. The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome. European Journal of Clinical Pharmacology. 69: 2065-72. PMID 23995862 DOI: 10.1007/S00228-013-1579-4 |
0.731 |
|
| 2013 |
Jacobs PL, Ridder L, Ruijken M, Rosing H, Jager NG, Beijnen JH, Bas RR, van Dongen WD. Identification of drug metabolites in human plasma or serum integrating metabolite prediction, LC-HRMS and untargeted data processing. Bioanalysis. 5: 2115-28. PMID 23962251 DOI: 10.4155/Bio.13.178 |
0.398 |
|
| 2013 |
Hendrikx JJ, Dubbelman AC, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Quantification of docetaxel and its metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 27: 1925-34. PMID 23939959 DOI: 10.1002/Rcm.6654 |
0.493 |
|
| 2013 |
Luethi D, Durmus S, Schinkel AH, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 934: 22-5. PMID 23892825 DOI: 10.1016/J.Jchromb.2013.06.030 |
0.509 |
|
| 2013 |
Goey AK, Meijerman I, Beijnen JH, Schellens JH. The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers. European Journal of Clinical Pharmacology. 69: 1883-90. PMID 23881421 DOI: 10.1007/S00228-013-1558-9 |
0.479 |
|
| 2013 |
Lau C, Mooiman KD, Maas-Bakker RF, Beijnen JH, Schellens JH, Meijerman I. Effect of Chinese herbs on CYP3A4 activity and expression in vitro. Journal of Ethnopharmacology. 149: 543-9. PMID 23876595 DOI: 10.1016/J.Jep.2013.07.014 |
0.516 |
|
| 2013 |
Tang SC, de Vries N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib. The Journal of Pharmacology and Experimental Therapeutics. 346: 486-94. PMID 23843632 DOI: 10.1124/Jpet.113.205583 |
0.328 |
|
| 2013 |
Stuurman FE, Lolkema MP, Huitema AD, Soetekouw PM, Rosing H, Rolfe L, Kaur P, Beijnen JH, van Tinteren H, Voest EE, Schellens JH. A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors. Journal of Clinical Pharmacology. 53: 878-83. PMID 23775853 DOI: 10.1002/Jcph.108 |
0.466 |
|
| 2013 |
Goey AK, Meijerman I, Rosing H, Burgers JA, Mergui-Roelvink M, Keessen M, Marchetti S, Beijnen JH, Schellens JH. The effect of Echinacea purpurea on the pharmacokinetics of docetaxel. British Journal of Clinical Pharmacology. 76: 467-74. PMID 23701184 DOI: 10.1111/Bcp.12159 |
0.533 |
|
| 2013 |
Mooiman KD, Maas-Bakker RF, Moret EE, Beijnen JH, Schellens JH, Meijerman I. Milk thistle's active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1494-504. PMID 23674609 DOI: 10.1124/Dmd.113.050971 |
0.511 |
|
| 2013 |
Mooiman KD, Maas-Bakker RF, Rosing H, Beijnen JH, Schellens JH, Meijerman I. Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures. Biomedical Chromatography : Bmc. 27: 1107-16. PMID 23674377 DOI: 10.1002/Bmc.2913 |
0.48 |
|
| 2013 |
Derissen EJ, Beijnen JH, Schellens JH. Concise drug review: azacitidine and decitabine. The Oncologist. 18: 619-24. PMID 23671007 DOI: 10.1634/Theoncologist.2012-0465 |
0.464 |
|
| 2013 |
Leijen S, Veltkamp SA, Huitema AD, van Werkhoven E, Beijnen JH, Schellens JH. Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer. Gynecologic Oncology. 130: 511-7. PMID 23665458 DOI: 10.1016/J.Ygyno.2013.05.001 |
0.759 |
|
| 2013 |
Jibodh RA, Lagas JS, Nuijen B, Beijnen JH, Schellens JH. Taxanes: old drugs, new oral formulations. European Journal of Pharmacology. 717: 40-6. PMID 23660368 DOI: 10.1016/J.Ejphar.2013.02.058 |
0.524 |
|
| 2013 |
Dorlo TP, Jager NG, Beijnen JH, Schellens JH. [Concomitant use of proton pump inhibitors and systemic corticosteroids]. Nederlands Tijdschrift Voor Geneeskunde. 157: A5540. PMID 23657097 |
0.358 |
|
| 2013 |
van Hasselt JG, Gupta A, Hussein Z, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia. British Journal of Clinical Pharmacology. 76: 412-24. PMID 23601153 DOI: 10.1111/Bcp.12143 |
0.804 |
|
| 2013 |
Kort A, Hillebrand MJ, Cirkel GA, Voest EE, Schinkel AH, Rosing H, Schellens JH, Beijnen JH. Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 925: 117-23. PMID 23542607 DOI: 10.1016/J.Jchromb.2013.02.034 |
0.531 |
|
| 2013 |
Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 925: 124-8. PMID 23537694 DOI: 10.1016/J.Jchromb.2013.02.025 |
0.507 |
|
| 2013 |
Deenen MJ, Dewit L, Boot H, Beijnen JH, Schellens JH, Cats A. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. International Journal of Radiation Oncology, Biology, Physics. 85: e201-7. PMID 23517808 DOI: 10.1016/J.Ijrobp.2012.12.008 |
0.513 |
|
| 2013 |
Lankheet NA, Steeghs N, Rosing H, Schellens JH, Beijnen JH, Huitema AD. Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring. Therapeutic Drug Monitoring. 35: 168-76. PMID 23503442 DOI: 10.1097/Ftd.0B013E31827Efd9E |
0.526 |
|
| 2013 |
Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JH, Beijnen JH, van Tellingen O. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2084-95. PMID 23461902 DOI: 10.1158/1078-0432.Ccr-12-3105 |
0.472 |
|
| 2013 |
Lin F, Buil L, Sherris D, Beijnen JH, van Tellingen O. Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. International Journal of Cancer. Journal International Du Cancer. 133: 1222-33. PMID 23436212 DOI: 10.1002/Ijc.28126 |
0.359 |
|
| 2013 |
van der Noll R, Leijen S, Neuteboom GH, Beijnen JH, Schellens JH. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treatment Reviews. 39: 664-72. PMID 23434072 DOI: 10.1016/J.Ctrv.2013.01.003 |
0.481 |
|
| 2013 |
Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TP, Beijnen JH, Vanaerschot M, Decuypere S, Dhakal SS, Das ML, Karki P, Singh R, Boelaert M, Dujardin JC. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 56: 1530-8. PMID 23425958 DOI: 10.1093/Cid/Cit102 |
0.338 |
|
| 2013 |
Lin F, Hoogendijk L, Buil L, Beijnen JH, van Tellingen O. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo. European Journal of Cancer (Oxford, England : 1990). 49: 2059-64. PMID 23422148 DOI: 10.1016/J.Ejca.2012.12.028 |
0.372 |
|
| 2013 |
Stuurman FE, Nuijen B, Beijnen JH, Schellens JH. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. Clinical Pharmacokinetics. 52: 399-414. PMID 23420518 DOI: 10.1007/S40262-013-0040-2 |
0.526 |
|
| 2013 |
Kromdijk W, Pereira SA, Rosing H, Mulder JW, Beijnen JH, Huitema AD. Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 919: 43-51. PMID 23411018 DOI: 10.1016/J.Jchromb.2013.01.005 |
0.369 |
|
| 2013 |
Goey AK, Mooiman KD, Beijnen JH, Schellens JH, Meijerman I. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treatment Reviews. 39: 773-83. PMID 23394826 DOI: 10.1016/J.Ctrv.2012.12.008 |
0.526 |
|
| 2013 |
Deenen MJ, Cats A, Beijnen JH, Schellens JH. Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients. Therapeutic Advances in Medical Oncology. 5: 91-2. PMID 23323150 DOI: 10.1177/1758834012464806 |
0.502 |
|
| 2013 |
Dubbelman AC, Rosing H, Darwish M, D'Andrea D, Bond M, Hellriegel E, Robertson P, Beijnen JH, Schellens JH. Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy. Drugs in R&D. 13: 17-28. PMID 23322528 DOI: 10.1007/S40268-012-0001-5 |
0.565 |
|
| 2013 |
Pluim D, Jacobs BA, Krähenbühl MD, Ruijter AE, Beijnen JH, Schellens JH. Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination. Analytical and Bioanalytical Chemistry. 405: 2391-5. PMID 23318760 DOI: 10.1007/S00216-012-6614-2 |
0.439 |
|
| 2013 |
Pluim D, Schilders KA, Jacobs BA, Vaartjes D, Beijnen JH, Schellens JH. Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells. Analytical and Bioanalytical Chemistry. 405: 2495-503. PMID 23314484 DOI: 10.1007/S00216-012-6676-1 |
0.457 |
|
| 2013 |
Zander SA, Beijnen JH, van Tellingen O. Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 913: 129-36. PMID 23291288 DOI: 10.1016/J.Jchromb.2012.11.003 |
0.346 |
|
| 2013 |
Harmsen S, Meijerman I, Maas-Bakker RF, Beijnen JH, Schellens JHM. PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors European Journal of Pharmaceutical Sciences. 48: 644-649. PMID 23277288 DOI: 10.1016/J.Ejps.2012.12.019 |
0.323 |
|
| 2013 |
Deenen MJ, Rosing H, Hillebrand MJ, Schellens JH, Beijnen JH. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 913: 30-40. PMID 23270936 DOI: 10.1016/J.Jchromb.2012.11.033 |
0.536 |
|
| 2013 |
Kromdijk W, Mulder JW, Smit PM, Ter Heine R, Beijnen JH, Huitema AD. Therapeutic drug monitoring of antiretroviral drugs at home using dried blood spots: a proof-of-concept study. Antiviral Therapy. 18: 821-5. PMID 23234680 DOI: 10.3851/Imp2501 |
0.701 |
|
| 2013 |
Meulenaar J, Beijnen JH, Schellens JH, Nuijen B. Slow dissolution behaviour of amorphous capecitabine. International Journal of Pharmaceutics. 441: 213-7. PMID 23219704 DOI: 10.1016/J.Ijpharm.2012.11.041 |
0.447 |
|
| 2013 |
Van Hasselt JGC, van Eijkelenburg NKA, Beijnen JH, Schellens JHM, Huitema ADR. Optimizing drug development of anti-cancer drugs in children using modelling and simulation British Journal of Clinical Pharmacology. 76: 30-47. PMID 23216601 DOI: 10.1111/Bcp.12062 |
0.73 |
|
| 2013 |
Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. International Journal of Cancer. Journal International Du Cancer. 132: 2439-47. PMID 23090875 DOI: 10.1002/Ijc.27912 |
0.47 |
|
| 2013 |
Milojkovic Kerklaan B, Kerklaan BM, Diéras V, Le Tourneau C, Mergui-Roelvink M, Huitema AD, Rosing H, Beijnen JH, Marreaud S, Govaerts AS, Piccart-Gebhart MJ, Schellens JH, Awada A. Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. Cancer Chemotherapy and Pharmacology. 71: 53-62. PMID 23053259 DOI: 10.1007/s00280-012-1972-1 |
0.734 |
|
| 2013 |
Lankheet NA, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH, Huitema AD. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Biomedical Chromatography : Bmc. 27: 466-76. PMID 22987603 DOI: 10.1002/Bmc.2814 |
0.527 |
|
| 2013 |
Devriese LA, Witteveen PE, Wanders J, Law K, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Huitema AD, Voest EE, Schellens JH. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. British Journal of Clinical Pharmacology. 75: 507-15. PMID 22803519 DOI: 10.1111/J.1365-2125.2012.04381.X |
0.765 |
|
| 2013 |
Devriese LA, Mergui-Roelvink M, Wanders J, Jenner A, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Schellens JHM. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole Investigational New Drugs. 31: 381-389. PMID 22555773 DOI: 10.1007/S10637-012-9829-3 |
0.432 |
|
| 2013 |
Moes J, Koolen S, Huitema A, Schellens J, Beijnen J, Nuijen B. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel European Journal of Pharmaceutics and Biopharmaceutics. 83: 87-94. DOI: 10.1016/J.Ejpb.2012.09.016 |
0.534 |
|
| 2012 |
Deenen MJ, Cats A, Mandigers CM, Soesan M, Terpstra WE, Beijnen JH, Schellens JH. [Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency]. Nederlands Tijdschrift Voor Geneeskunde. 156: A4934. PMID 23191966 |
0.444 |
|
| 2012 |
Lankheet NA, Schaake EE, Rosing H, Burgers JA, Schellens JH, Beijnen JH, Huitema AD. Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue. Bioanalysis. 4: 2563-77. PMID 23173792 DOI: 10.4155/Bio.12.235 |
0.466 |
|
| 2012 |
Moes J, Koolen S, Huitema A, Schellens J, Beijnen J, Nuijen B. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. 83: 87-94. PMID 23085332 DOI: 10.1016/j.ejpb.2012.09.016 |
0.739 |
|
| 2012 |
Devriese LA, Witteveen PO, Marchetti S, Mergui-Roelvink M, Reyderman L, Wanders J, Jenner A, Edwards G, Beijnen JH, Voest EE, Schellens JHM. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment Cancer Chemotherapy and Pharmacology. 70: 823-832. PMID 23010853 DOI: 10.1007/S00280-012-1976-X |
0.303 |
|
| 2012 |
Dubbelman AC, Upthagrove A, Beijnen JH, Marchetti S, Tan E, Krone K, Anand S, Schellens JH. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 70: 653-63. PMID 23010851 DOI: 10.1007/S00280-012-1947-2 |
0.546 |
|
| 2012 |
Sparidans RW, Tang SC, Nguyen LN, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 905: 150-4. PMID 22940474 DOI: 10.1016/J.Jchromb.2012.08.021 |
0.508 |
|
| 2012 |
Sparidans RW, Ahmed TTA, Muilwijk EW, Welzen MEB, Schellens JHM, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 905: 137-140. PMID 22917595 DOI: 10.1016/J.Jchromb.2012.08.004 |
0.359 |
|
| 2012 |
Van Hasselt JGC, Schellens JHM, Mac Gillavry MR, Beijnen JH, Huitema ADR. Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab Pharmaceutical Research. 29: 3499-3511. PMID 22907417 DOI: 10.1007/S11095-012-0845-Y |
0.721 |
|
| 2012 |
Dorlo TPC, Balasegaram M, Beijnen JH, de vries PJ. Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis Journal of Antimicrobial Chemotherapy. 67: 2576-2597. PMID 22833634 DOI: 10.1093/Jac/Dks275 |
0.344 |
|
| 2012 |
Iusuf D, Sparidans RW, van Esch A, Hobbs M, Kenworthy KE, van de Steeg E, Wagenaar E, Beijnen JH, Schinkel AH. Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice. Molecular Pharmaceutics. 9: 2497-504. PMID 22812517 DOI: 10.1021/Mp300108C |
0.304 |
|
| 2012 |
Joerger M, Kraff S, Huitema AD, Feiss G, Moritz B, Schellens JH, Beijnen JH, Jaehde U. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clinical Pharmacokinetics. 51: 607-17. PMID 22804749 DOI: 10.1007/Bf03261934 |
0.765 |
|
| 2012 |
Goey AK, Rosing H, Meijerman I, Sparidans RW, Schellens JH, Beijnen JH. The bioanalysis of the major Echinacea purpurea constituents dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides in human plasma using LC-MS/MS. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 902: 151-6. PMID 22770780 DOI: 10.1016/J.Jchromb.2012.06.022 |
0.486 |
|
| 2012 |
Lagas JS, Damen CWN, Van Waterschoot RAB, Iusuf D, Beijnen JH, Schinkel AH. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine Molecular Pharmacology. 82: 636-644. PMID 22767610 DOI: 10.1124/Mol.111.077099 |
0.32 |
|
| 2012 |
van Geel RM, Beijnen JH, Schellens JH. Concise drug review: pazopanib and axitinib. The Oncologist. 17: 1081-9. PMID 22733795 DOI: 10.1634/Theoncologist.2012-0055 |
0.507 |
|
| 2012 |
Lin F, Chandrasekaran G, de Gooijer MC, Beijnen JH, van Tellingen O. Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 901: 9-17. PMID 22727754 DOI: 10.1016/J.Jchromb.2012.05.033 |
0.335 |
|
| 2012 |
Dorlo TP, Eggelte TA, Schoone GJ, de Vries PJ, Beijnen JH. A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal. Plos Neglected Tropical Diseases. 6: e1544. PMID 22666507 DOI: 10.1371/Journal.Pntd.0001544 |
0.334 |
|
| 2012 |
Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses. The Aaps Journal. 14: 601-11. PMID 22648902 DOI: 10.1208/S12248-012-9373-2 |
0.708 |
|
| 2012 |
Dorlo TP, Huitema AD, Beijnen JH, de Vries PJ. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrobial Agents and Chemotherapy. 56: 3864-72. PMID 22585212 DOI: 10.1128/Aac.00292-12 |
0.683 |
|
| 2012 |
van Hasselt JG, van den Heuvel MM, Schellens JH, Beijnen JH, Brandsma D, Huitema AD. Severe cannabinoid intoxication in a patient with non-small-cell lung cancer. Journal of Palliative Care. 28: 60-1. PMID 22582474 |
0.771 |
|
| 2012 |
Dorlo TP, Balasegaram M, Lima MA, de Vries PJ, Beijnen JH, Huitema AD. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. The Journal of Antimicrobial Chemotherapy. 67: 1996-2004. PMID 22577099 DOI: 10.1093/Jac/Dks164 |
0.712 |
|
| 2012 |
Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O'Brien JP, Schellens JH, Evans TR. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. British Journal of Cancer. 106: 1598-604. PMID 22516948 DOI: 10.1038/Bjc.2012.154 |
0.484 |
|
| 2012 |
Mooiman KD, Goey AK, Meijerman I, Beijnen JH, Schellens JH. Letter to the editor regarding "A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer" by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197-1202). The Oncologist. 17: 740-1; author reply . PMID 22511266 DOI: 10.1634/Theoncologist.2011-0413 |
0.51 |
|
| 2012 |
Dubbelman AC, Jansen RS, Rosing H, Darwish M, Hellriegel E, Robertson P, Schellens JH, Beijnen JH. Metabolite profiling of bendamustine in urine of cancer patients after administration of [14C]bendamustine. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1297-307. PMID 22492615 DOI: 10.1124/Dmd.112.045229 |
0.48 |
|
| 2012 |
Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. Lapatinib for advanced or metastatic breast cancer. The Oncologist. 17: 536-42. PMID 22477724 DOI: 10.1634/Theoncologist.2011-0461 |
0.456 |
|
| 2012 |
Sparidans RW, Durmus S, Xu N, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 169-73. PMID 22476055 DOI: 10.1016/J.Jchromb.2012.03.020 |
0.515 |
|
| 2012 |
Sparidans RW, Durmus S, Xu N, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 174-7. PMID 22476054 DOI: 10.1016/J.Jchromb.2012.03.021 |
0.504 |
|
| 2012 |
Dubbelman AC, Tibben M, Rosing H, Gebretensae A, Nan L, Gorman SH, Robertson P, Schellens JH, Beijnen JH. Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 893: 92-100. PMID 22426286 DOI: 10.1016/J.Jchromb.2012.02.039 |
0.516 |
|
| 2012 |
Kromdijk W, Rosing H, van den Broek MP, Beijnen JH, Huitema AD. Quantitative determination of oseltamivir and oseltamivir carboxylate in human fluoride EDTA plasma including the ex vivo stability using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 891: 57-63. PMID 22418071 DOI: 10.1016/J.Jchromb.2012.02.026 |
0.364 |
|
| 2012 |
Jager NG, Rosing H, Linn SC, Schellens JH, Beijnen JH. Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen. Breast Cancer Research and Treatment. 133: 793-8. PMID 22388692 DOI: 10.1007/S10549-012-2000-1 |
0.472 |
|
| 2012 |
Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 144-7. PMID 22386128 DOI: 10.1016/J.Jchromb.2012.02.010 |
0.509 |
|
| 2012 |
Jansen RS, Rosing H, Wijermans PW, Keizer RJ, Schellens JH, Beijnen JH. Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study. Cancer Chemotherapy and Pharmacology. 69: 1457-66. PMID 22382880 DOI: 10.1007/S00280-012-1850-X |
0.477 |
|
| 2012 |
Dubbelman AC, Rosing H, Thijssen B, Gebretensae A, Lucas L, Chen H, Shumaker R, Schellens JHM, Beijnen JH. Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 887: 25-34. PMID 22309776 DOI: 10.1016/J.Jchromb.2012.01.004 |
0.313 |
|
| 2012 |
Kromdijk W, Mulder JW, Rosing H, Smit PM, Beijnen JH, Huitema AD. Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz. The Journal of Antimicrobial Chemotherapy. 67: 1211-6. PMID 22302563 DOI: 10.1093/Jac/Dks011 |
0.712 |
|
| 2012 |
Keizer RJ, Gupta A, Shumaker R, Beijnen JH, Schellens JH, Huitema AD. Model-based treatment optimization of a novel VEGFR inhibitor. British Journal of Clinical Pharmacology. 74: 315-26. PMID 22295876 DOI: 10.1111/J.1365-2125.2012.04197.X |
0.754 |
|
| 2012 |
Vermaat JS, Gerritse FL, Van Der Veldt AA, Roessingh WM, Niers TM, Oosting SF, Sleijfer S, Roodhart JM, Beijnen JH, Schellens JH, Gietema JA, Boven E, Richel DJ, Haanen JB, Voest EE. Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients European Urology. 62: 685-696. PMID 22285764 DOI: 10.1016/J.Eururo.2012.01.020 |
0.488 |
|
| 2012 |
Dubbelman AC, Rosing H, Schellens JH, Beijnen JH. Bioanalytical aspects of clinical mass balance studies in oncology. Bioanalysis. 3: 2637-55. PMID 22136052 DOI: 10.4155/Bio.11.276 |
0.497 |
|
| 2012 |
Dubbelman AC, Rosing H, Jansen RS, Mergui-Roelvink M, Huitema AD, Koetz B, Lymboura M, Reyderman L, Lopez-Anaya A, Schellens JH, Beijnen JH. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 313-21. PMID 22041109 DOI: 10.1124/Dmd.111.042762 |
0.755 |
|
| 2012 |
Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema AD, Beijnen JH, Schellens JH. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer. 118: 2466-75. PMID 22031394 DOI: 10.1002/Cncr.26562 |
0.726 |
|
| 2012 |
Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152). Investigational New Drugs. 30: 1519-30. PMID 21626115 DOI: 10.1007/S10637-011-9694-5 |
0.749 |
|
| 2012 |
Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS, Vainchtein LD, Rosing H, Huitema AD, Beijnen JH, Schellens JH. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemotherapy and Pharmacology. 69: 25-33. PMID 21590444 DOI: 10.1007/S00280-011-1670-4 |
0.538 |
|
| 2012 |
Koolen SL, van Waterschoot RA, van Tellingen O, Schinkel AH, Beijnen JH, Schellens JH, Huitema AD. From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies. Journal of Clinical Pharmacology. 52: 370-80. PMID 21505085 DOI: 10.1177/0091270010397051 |
0.525 |
|
| 2012 |
van den Berg H, van den Anker JN, Beijnen JH. Cytostatic drugs in infants: a review on pharmacokinetic data in infants. Cancer Treatment Reviews. 38: 3-26. PMID 21489698 DOI: 10.1016/J.Ctrv.2011.03.005 |
0.303 |
|
| 2012 |
Keizer RJ, Budde IK, Sprengers PF, Levi M, Beijnen JH, Huitema AD. Model-based evaluation of similarity in pharmacokinetics of two formulations of the blood-derived plasma product c1 esterase inhibitor. Journal of Clinical Pharmacology. 52: 204-13. PMID 21263014 DOI: 10.1177/0091270010394446 |
0.691 |
|
| 2012 |
Nannan Panday VR, van Warmerdam LJ, Huizing MT, Ten Bokkel Huinink WW, Vermorken JB, Giaccone G, Veenhof CH, Schellens JH, Beijnen JH. Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens. Clinical Drug Investigation. 15: 327-35. PMID 18370488 DOI: 10.2165/00044011-199815040-00009 |
0.497 |
|
| 2012 |
Lankheet NAG, Kloth JSL, Hooijdonk CGMG, Cirkel GA, Mathijssen RHJ, Lolkema MPJK, Schellens JHM, Voest EE, Sleijfer S, Beijnen JH, Huitema ADR, Steeghs N. Individual PK-guided sunitinib dosing: A feasibility study in patients with advanced solid tumors. Journal of Clinical Oncology. 30: 2596-2596. DOI: 10.1200/Jco.2012.30.15_Suppl.2596 |
0.381 |
|
| 2012 |
Marchetti S, Stuurman F, Koolen S, Moes J, Hendrikx J, Thijssen B, Huitema AD, Nuijen B, Rosing H, Keessen M, Voest EE, Mergui-Roelvink M, Beijnen JH, Schellens JHM. Phase I study of weekly oral docetaxel (ModraDoc001) plus ritonavir in patients with advanced solid tumors. Journal of Clinical Oncology. 30: 2550-2550. DOI: 10.1200/Jco.2012.30.15_Suppl.2550 |
0.413 |
|
| 2012 |
van Hasselt JC, van den Heuvel MM, Schellens JH, Beijnen JH, Brandsma D, Huitema A. Severe Cannabinoid Intoxication in A Patient with Non-Small-Cell Lung Cancer Journal of Palliative Care. 28: 60-61. DOI: 10.1177/082585971202800110 |
0.734 |
|
| 2012 |
Goey AKL, Meijerman I, Rosing H, Keessen M, Beijnen JH, Schellens JHM. Abstract 761: Phase I interaction study of docetaxel with supplementation of St. John's wort Cancer Research. 72: 761-761. DOI: 10.1158/1538-7445.Am2012-761 |
0.411 |
|
| 2012 |
Gooijer MCd, Lin F, Gasparini A, Vries NAd, Buil LCM, Wurdinger T, Sonke J, Beijnen JH, Tellingen OV. Abstract 5718: Implementation of μ-Image Guided Radio-Therapy in the treatment of experimental glioma mouse models: Assessment of the potential of agents that interfere with DNA repair Cancer Research. 72: 5718-5718. DOI: 10.1158/1538-7445.Am2012-5718 |
0.318 |
|
| 2012 |
Gaillard PJ, Gladdines W, Appeldoorn CCM, Rip J, Boogerd WJ, Beijnen JH, Brandsma D, Tellingen Ov. Abstract 5687: Development of glutathione pegylated liposomal doxorubicin (2B3-101) for the treatment of brain cancer Cancer Research. 72: 5687-5687. DOI: 10.1158/1538-7445.Am2012-5687 |
0.337 |
|
| 2012 |
Mooiman KD, Maas-Bakker RFM, Beijnen JH, Schellens JHM, Meijerman I. Abstract 3791: Milk thistle as an inhibitor of PXR-mediated CYP3A4 induction Cancer Research. 72: 3791-3791. DOI: 10.1158/1538-7445.Am2012-3791 |
0.334 |
|
| 2011 |
Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema A, Beijnen JH, Schellens JH. Drug pathway-associated gene polymorphisms in patients with advanced non-small cell lung cancer receiving first-line platinum-gemcitabine combination chemotherapy: A prospective multicenter observational study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7536. PMID 28023228 DOI: 10.1200/Jco.2011.29.15_Suppl.7536 |
0.402 |
|
| 2011 |
Devriese LA, Witteveen P, Voest EE, Overkleeft EN, Langenberg M, Beijnen JH, Reyderman L, Wanders J, Mould DR, Gupta A, Hussein Z, Schellens JH. Eribulin dosing in patients with advanced solid tumors and hepatic impairment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2544. PMID 28022319 DOI: 10.1200/jco.2011.29.15_suppl.2544 |
0.419 |
|
| 2011 |
Bergamo A, Gaiddon C, Schellens JH, Beijnen JH, Sava G. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. Journal of Inorganic Biochemistry. 106: 90-9. PMID 22112845 DOI: 10.1016/J.Jinorgbio.2011.09.030 |
0.489 |
|
| 2011 |
Lin F, Sherris D, Beijnen JH, Van Tellingen O. High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 3823-31. PMID 22100549 DOI: 10.1016/J.Jchromb.2011.10.028 |
0.376 |
|
| 2011 |
Lankheet NA, Blank CU, Mallo H, Adriaansz S, Rosing H, Schellens JH, Huitema AD, Beijnen JH. Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. Journal of Analytical Toxicology. 35: 558-65. PMID 22004675 DOI: 10.1093/Anatox/35.8.558 |
0.737 |
|
| 2011 |
Hendrikx JJ, Hillebrand MJ, Thijssen B, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 2984-90. PMID 21920826 DOI: 10.1016/J.Jchromb.2011.08.034 |
0.522 |
|
| 2011 |
Gast MC, Zapatka M, van Tinteren H, Bontenbal M, Span PN, Tjan-Heijnen VC, Knol JC, Jimenez CR, Schellens JH, Beijnen JH. Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer. Journal of Cancer Research and Clinical Oncology. 137: 1773-83. PMID 21913038 DOI: 10.1007/S00432-011-1055-4 |
0.444 |
|
| 2011 |
Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-Töns JH, Adriaansz S, Sprangers S, Nuijen B, Beijnen JH, Schellens JH. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3862-8. PMID 21911720 DOI: 10.1200/Jco.2010.33.1298 |
0.456 |
|
| 2011 |
Moes JJ, Koolen SL, Huitema AD, Schellens JH, Beijnen JH, Nuijen B. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). International Journal of Pharmaceutics. 420: 244-50. PMID 21907780 DOI: 10.1016/J.Ijpharm.2011.08.041 |
0.525 |
|
| 2011 |
Caron WP, Clewell H, Dedrick R, Ramanathan RK, Davis WL, Yu N, Tonda M, Schellens JH, Beijnen JH, Zamboni WC. Allometric scaling of pegylated liposomal anticancer drugs. Journal of Pharmacokinetics and Pharmacodynamics. 38: 653-69. PMID 21863380 DOI: 10.1007/S10928-011-9213-5 |
0.487 |
|
| 2011 |
Deenen MJ, Klümpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, Schellens JH, Wilmink JW. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Investigational New Drugs. 30: 1557-65. PMID 21809026 DOI: 10.1007/S10637-011-9723-4 |
0.499 |
|
| 2011 |
de Graan AJ, Teunissen SF, de Vos FY, Loos WJ, van Schaik RH, de Jongh FE, de Vos AI, van Alphen RJ, van der Holt B, Verweij J, Seynaeve C, Beijnen JH, Mathijssen RH. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3240-6. PMID 21768449 DOI: 10.1200/Jco.2010.32.9839 |
0.361 |
|
| 2011 |
Koolen SL, Witteveen PO, Jansen RS, Langenberg MH, Kronemeijer RH, Nol A, Garcia-Ribas I, Callies S, Benhadji KA, Slapak CA, Beijnen JH, Voest EE, Schellens JH. Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6071-82. PMID 21753156 DOI: 10.1158/1078-0432.Ccr-11-0353 |
0.524 |
|
| 2011 |
Tran L, Baars J, Damen C, Beijnen J, Huitema A. Three spectroscopic techniques evaluated as a tool to study the effects of iodination of monoclonal antibodies, exemplified by rituximab. Journal of Pharmaceutical and Biomedical Analysis. 56: 609-14. PMID 21723685 DOI: 10.1016/J.Jpba.2011.05.026 |
0.659 |
|
| 2011 |
Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects. The Oncologist. 16: 1006-20. PMID 21659612 DOI: 10.1634/Theoncologist.2010-0261 |
0.49 |
|
| 2011 |
Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism. The Oncologist. 16: 992-1005. PMID 21659608 DOI: 10.1634/Theoncologist.2010-0260 |
0.491 |
|
| 2011 |
van den Hoven JM, Van Tomme SR, Metselaar JM, Nuijen B, Beijnen JH, Storm G. Liposomal drug formulations in the treatment of rheumatoid arthritis. Molecular Pharmaceutics. 8: 1002-15. PMID 21634436 DOI: 10.1021/Mp2000742 |
0.327 |
|
| 2011 |
Van Hasselt JGC, Boekhout AH, Beijnen JH, Schellens JHM, Huitema ADR. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab- associated cardiotoxicity Clinical Pharmacology and Therapeutics. 90: 126-132. PMID 21633346 DOI: 10.1038/Clpt.2011.74 |
0.742 |
|
| 2011 |
Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. The Oncologist. 16: 820-34. PMID 21632461 DOI: 10.1634/Theoncologist.2010-0259 |
0.505 |
|
| 2011 |
Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab. The Oncologist. 16: 800-10. PMID 21632460 DOI: 10.1634/theoncologist.2010-0035 |
0.4 |
|
| 2011 |
Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 1: background, methodology, and clinical adoption of pharmacogenetics. The Oncologist. 16: 811-9. PMID 21632456 DOI: 10.1634/theoncologist.2010-0258 |
0.445 |
|
| 2011 |
Sparidans RW, Martens I, Valkenburg-van Iersel LB, den Hartigh J, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 1851-6. PMID 21622034 DOI: 10.1016/J.Jchromb.2011.05.003 |
0.534 |
|
| 2011 |
Devriese LA, Voest EE, Beijnen JH, Schellens JH. Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials. Cancer Treatment Reviews. 37: 579-89. PMID 21592671 DOI: 10.1016/j.ctrv.2011.04.006 |
0.397 |
|
| 2011 |
Ter Heine R, Mulder JW, van Gorp EC, Wagenaar JF, Beijnen JH, Huitema AD. Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples. Bioanalysis. 3: 1093-7. PMID 21585304 DOI: 10.4155/Bio.11.72 |
0.723 |
|
| 2011 |
Tran L, Baars JW, de Boer JP, Hoefnagel CA, Beijnen JH, Huitema AD. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab. Human Antibodies. 20: 37-40. PMID 21558622 DOI: 10.3233/Hab-2011-0240 |
0.329 |
|
| 2011 |
Teunissen SF, Jager NG, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 1677-85. PMID 21543272 DOI: 10.1016/J.Jchromb.2011.04.011 |
0.506 |
|
| 2011 |
Joerger M, deJong D, Burylo A, Burgers JA, Baas P, Huitema AD, Beijnen JH, Schellens JH. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer (Amsterdam, Netherlands). 74: 310-7. PMID 21529986 DOI: 10.1016/J.Lungcan.2011.03.016 |
0.471 |
|
| 2011 |
Boss DS, Glen H, Beijnen JH, de Jong D, Wanders J, Evans TR, Schellens JH. Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report. Tumori. 97: 109-14. PMID 21528673 |
0.332 |
|
| 2011 |
Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJ, Schellens JH, Cats A. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3455-68. PMID 21498394 DOI: 10.1158/1078-0432.Ccr-10-2209 |
0.424 |
|
| 2011 |
ter Heine R, Van Waterschoot RA, Keizer RJ, Beijnen JH, Schinkel AH, Huitema AD. An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir. Journal of Pharmaceutical Sciences. 100: 2508-15. PMID 21491455 DOI: 10.1002/Jps.22457 |
0.683 |
|
| 2011 |
Dubbelman AC, Rosing H, Thijssen B, Lucas L, Copalu W, Wanders J, Schellens JH, Beijnen JH. Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 1149-55. PMID 21458392 DOI: 10.1016/J.Jchromb.2011.03.021 |
0.519 |
|
| 2011 |
Janssens T, Brouwers EE, de Vos JP, Schellens JH, Beijnen JH. Determination of platinum originating from carboplatin in human urine and canine excretion products by inductively coupled plasma mass spectrometry. Journal of Analytical Toxicology. 35: 153-61. PMID 21439151 DOI: 10.1093/Anatox/35.3.153 |
0.484 |
|
| 2011 |
Teunissen SF, Rosing H, Seoane MD, Brunsveld L, Schellens JH, Schinkel AH, Beijnen JH. Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques. Journal of Pharmaceutical and Biomedical Analysis. 55: 518-26. PMID 21392921 DOI: 10.1016/J.Jpba.2011.02.009 |
0.317 |
|
| 2011 |
Keizer RJ, Funahashi Y, Semba T, Wanders J, Beijnen JH, Schellens JH, Huitema AD. Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies. The Aaps Journal. 13: 230-9. PMID 21387147 DOI: 10.1208/S12248-011-9260-2 |
0.481 |
|
| 2011 |
Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. International Journal of Cancer. 130: 223-33. PMID 21351087 DOI: 10.1002/Ijc.26000 |
0.329 |
|
| 2011 |
Lankheet NA, Padberg RD, de Kluiver EM, Wilhelm AJ, van Woensel JB, Beijnen JH, Huitema AD. Relatively mild symptoms after an olanzapine intoxication in a 2-year-old girl with excessively high serum levels. Journal of Child and Adolescent Psychopharmacology. 21: 93-5. PMID 21288123 DOI: 10.1089/Cap.2010.0110 |
0.647 |
|
| 2011 |
Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 729-35. PMID 21282407 DOI: 10.1124/Dmd.110.037317 |
0.32 |
|
| 2011 |
Keizer RJ, Schellens JH, Beijnen JH, Huitema AD. Pharmacodynamic biomarkers in model-based drug development in oncology. Current Clinical Pharmacology. 6: 30-40. PMID 21235464 DOI: 10.2174/157488411794941368 |
0.745 |
|
| 2011 |
van den Broek I, Sparidans RW, Engwegen JY, Cats A, Depla AC, Schellens JH, Beijnen JH. Evaluation of human neutrophil peptide-1, -2 and -3 as serum markers for colorectal cancer. Cancer Biomarkers : Section a of Disease Markers. 7: 109-15. PMID 21178269 DOI: 10.3233/Cbm-2010-0153 |
0.441 |
|
| 2011 |
van den Broek I, Sparidans RW, van Winden AW, Gast MC, van Dulken EJ, Schellens JH, Beijnen JH. The absolute quantification of eight inter-α-trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients. Proteomics. Clinical Applications. 4: 931-9. PMID 21137033 DOI: 10.1002/Prca.201000035 |
0.445 |
|
| 2011 |
Lagas JS, Wagenaar JF, Huitema AD, Hillebrand MJ, Koks CH, Gerdes VE, Brandjes DP, Beijnen JH. Lethal morphine intoxication in a patient with a sickle cell crisis and renal impairment: case report and a review of the literature. Human & Experimental Toxicology. 30: 1399-403. PMID 21056950 DOI: 10.1177/0960327110388962 |
0.674 |
|
| 2011 |
Tulner LR, van Campen JP, Frankfort SV, Koks CH, Beijnen JH, Brandjes DP, Jansen PA. Changes in under-treatment after comprehensive geriatric assessment: an observational study. Drugs & Aging. 27: 831-43. PMID 20883063 DOI: 10.2165/11539330-000000000-00000 |
0.322 |
|
| 2011 |
Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Computer Methods and Programs in Biomedicine. 101: 72-9. PMID 20627442 DOI: 10.1016/J.Cmpb.2010.04.018 |
0.699 |
|
| 2011 |
Jansen RS, Rosing H, Schellens JH, Beijnen JH. Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs. Mass Spectrometry Reviews. 30: 321-43. PMID 20623700 DOI: 10.1002/Mas.20280 |
0.458 |
|
| 2011 |
Soto E, Keizer RJ, Trocóniz IF, Huitema AD, Beijnen JH, Schellens JH, Wanders J, Cendrós JM, Obach R, Peraire C, Friberg LE, Karlsson MO. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. Investigational New Drugs. 29: 984-95. PMID 20449627 DOI: 10.1007/S10637-010-9437-Z |
0.74 |
|
| 2011 |
Appels NM, Bolijn MJ, van Eijndhoven MA, Stephens TC, Beijnen JH, Schellens JH. Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor. Cancer Chemotherapy and Pharmacology. 67: 137-45. PMID 20229082 DOI: 10.1007/S00280-010-1300-6 |
0.407 |
|
| 2011 |
Jansen RS, Rosing H, Schellens JH, Beijnen JH. Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites? Fundamental & Clinical Pharmacology. 25: 172-85. PMID 20199587 DOI: 10.1111/J.1472-8206.2010.00823.X |
0.461 |
|
| 2011 |
Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 1: Background, Methodology, and Clinical Adoption of Pharmacogenetics The Oncologist. 16: 811-819. DOI: 10.1634/Theoncologist.2010-0258 |
0.515 |
|
| 2011 |
Dubbelman A, Rosing H, Darwish M, D'Andrea D, Bond M, Hellriegel ET, Beijnen JH, Schellens JHM. An Open-Label Phase I Pharmacokinetic Study of [14c] Bendamustine in Patients with Relapsed or Refractory Malignancy Blood. 118: 2476-2476. DOI: 10.1182/Blood.V118.21.2476.2476 |
0.419 |
|
| 2011 |
Boss DS, Glen H, Beijnen JH, de Jong D, Wanders J, Evans TJ, Schellens JH. Serum β-HCG and CA-125 as Tumor Markers in a Patient with Osteosarcoma: Case Report Tumori Journal. 97: 109-114. DOI: 10.1177/030089161109700119 |
0.44 |
|
| 2011 |
Fan L, Gooijer MCd, Beumer JH, Christner SM, Beijnen JH, Tellingen OV. Abstract LB-210: Impact of ABC-transporters in the blood-brain barrier on the efficacy of the PARP inhibitor ABT-888 against transplanted and spontaneous murine brain tumors Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-210 |
0.343 |
|
| 2011 |
Caron WP, Clewell H, Dedrick R, Ramanathan RK, Yu N, Schellens JH, Beijnen JH, Zamboni WC. Abstract 373: Allometric scaling of the pharmacokinetics of pegylated liposomal anticancer drugs Cancer Research. 71: 373-373. DOI: 10.1158/1538-7445.Am2011-373 |
0.334 |
|
| 2011 |
Devriese L, Witteveen P, Marchetti S, Reyderman L, Edwards G, Law K, Wanders J, Beijnen J, Voest E, Schellens J. 1243 POSTER Eribulin Mesylate Pharmacokinetics in Patients With Advanced Solid Tumours Receiving Rifampicin European Journal of Cancer. 47: S157. DOI: 10.1016/S0959-8049(11)70855-3 |
0.321 |
|
| 2011 |
Devriese LA, Voest EE, Beijnen JH, Schellens JH. Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials Cancer Treatment Reviews. 37: 579-589. DOI: 10.1016/J.Ctrv.2011.04.006 |
0.473 |
|
| 2011 |
Teunissen SF, Rosing H, Brunsveld L, de Greef TFA, Durmus S, Schellens JHM, Schinkel AH, Beijnen JH. Analysis of 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and Its Phase I and Phase II Metabolites in Mouse Urine Using LC–UV–MS–MS Chromatographia. 74: 215-226. DOI: 10.1007/S10337-011-2068-5 |
0.308 |
|
| 2010 |
Helgason HH, Engwegen JY, Zapatka M, Cats A, Boot H, Beijnen JH, Schellens JH. Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer. Oncology Letters. 1: 327-333. PMID 22966303 DOI: 10.3892/Ol_00000058 |
0.486 |
|
| 2010 |
Waterschoot RABv, Lagas JS, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. International Journal of Cancer. 127: 2959-2964. PMID 21351274 DOI: 10.1002/Ijc.25279 |
0.313 |
|
| 2010 |
Klümpen HJ, Beijnen JH, Gurney H, Schellens JH. Inhibitors of mTOR. The Oncologist. 15: 1262-9. PMID 21147869 DOI: 10.1634/Theoncologist.2010-0196 |
0.495 |
|
| 2010 |
van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers. Clinical Proteomics. 6: 115-127. PMID 21124649 DOI: 10.1007/S12014-010-9054-Z |
0.473 |
|
| 2010 |
Goey AK, Sparidans RW, Meijerman I, Rosing H, Schellens JH, Beijnen JH. A sensitive LC-MS/MS method for the quantitative analysis of the Echinacea purpurea constituent undeca-2-ene-8,10-diynoic acid isobutylamide in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 41-8. PMID 21123121 DOI: 10.1016/J.Jchromb.2010.11.007 |
0.495 |
|
| 2010 |
Teunissen SF, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Review on the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and its phase I and phase II metabolites in biological matrices, foodstuff and beverages. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 3199-216. PMID 21071289 DOI: 10.1016/J.Jchromb.2010.10.018 |
0.303 |
|
| 2010 |
de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Investigational New Drugs. 30: 443-9. PMID 20963470 DOI: 10.1007/S10637-010-9569-1 |
0.464 |
|
| 2010 |
Janssens T, Brouwers EE, de Vos JP, Schellens JH, Beijnen JH. Determination of platinum originating from carboplatin in canine sebum and cerumen by inductively coupled plasma mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 54: 395-400. PMID 20933356 DOI: 10.1016/J.Jpba.2010.09.014 |
0.479 |
|
| 2010 |
Sparidans RW, Iusuf D, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 2751-9. PMID 20829130 DOI: 10.1016/J.Jchromb.2010.08.015 |
0.522 |
|
| 2010 |
Teunissen SF, Vlaming ML, Rosing H, Schellens JH, Schinkel AH, Beijnen JH. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and its metabolite 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) in plasma, urine, bile, intestinal contents, faeces and eight selected tissues from mice. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 2353-62. PMID 20708442 DOI: 10.1016/J.Jchromb.2010.07.012 |
0.491 |
|
| 2010 |
Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. The Oncologist. 15: 819-25. PMID 20688807 DOI: 10.1634/theoncologist.2009-0317 |
0.31 |
|
| 2010 |
Keizer RJ, Gupta A, Mac Gillavry MR, Jansen M, Wanders J, Beijnen JH, Schellens JH, Karlsson MO, Huitema AD. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. Journal of Pharmacokinetics and Pharmacodynamics. 37: 347-63. PMID 20652729 DOI: 10.1007/S10928-010-9164-2 |
0.745 |
|
| 2010 |
Brandsma D, Dorlo TP, Haanen JH, Beijnen JH, Boogerd W. Severe encephalopathy and polyneuropathy induced by dichloroacetate. Journal of Neurology. 257: 2099-100. PMID 20632025 DOI: 10.1007/S00415-010-5654-9 |
0.351 |
|
| 2010 |
Sparidans RW, Langendijk P, Boers E, van Kan E, Tan HL, Beijnen JH. Liquid chromatographic assay with fluorescence detection to determine ajmaline in serum from patients with suspected Brugada syndrome. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 2168-72. PMID 20620121 DOI: 10.1016/J.Jchromb.2010.06.017 |
0.347 |
|
| 2010 |
Goey AK, Schellens JH, Beijnen JH, Huitema AD. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation]. Nederlands Tijdschrift Voor Geneeskunde. 154: A1155. PMID 20619024 |
0.7 |
|
| 2010 |
Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clinical Pharmacokinetics. 49: 493-507. PMID 20608753 DOI: 10.2165/11531280-000000000-00000 |
0.729 |
|
| 2010 |
Buikhuisen WA, Burgers JA, Vincent AD, Schellens JH, Beijnen JH, Smit EF, Joerger M. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: e482-3; author reply. PMID 20606096 DOI: 10.1200/Jco.2010.29.1559 |
0.469 |
|
| 2010 |
Sparidans RW, van Velsen SG, de Roos MP, Schellens JH, Bruijnzeel-Koomen CA, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for clobetasol propionate in human serum from patients with atopic dermatitis. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 2150-4. PMID 20605116 DOI: 10.1016/J.Jchromb.2010.06.011 |
0.501 |
|
| 2010 |
van Waterschoot RA, ter Heine R, Wagenaar E, van der Kruijssen CM, Rooswinkel RW, Huitema AD, Beijnen JH, Schinkel AH. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. British Journal of Pharmacology. 160: 1224-33. PMID 20590614 DOI: 10.1111/J.1476-5381.2010.00759.X |
0.308 |
|
| 2010 |
Ter Heine R, Mulder JW, van Gorp EC, Wagenaar JF, Beijnen JH, Huitema AD. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. British Journal of Clinical Pharmacology. 69: 475-83. PMID 20573083 DOI: 10.1111/J.1365-2125.2010.03634.X |
0.744 |
|
| 2010 |
Koolen SL, Oostendorp RL, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. British Journal of Clinical Pharmacology. 69: 465-74. PMID 20573082 DOI: 10.1111/J.1365-2125.2010.03621.X |
0.759 |
|
| 2010 |
van Winden AW, van den Broek I, Gast MC, Engwegen JY, Sparidans RW, van Dulken EJ, Depla AC, Cats A, Schellens JH, Peeters PH, Beijnen JH, van Gils CH. Serum degradome markers for the detection of breast cancer. Journal of Proteome Research. 9: 3781-8. PMID 20557135 DOI: 10.1021/Pr100395S |
0.459 |
|
| 2010 |
Tran L, Baars JW, Aarden L, Beijnen JH, Huitema AD. Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. Human Antibodies. 19: 7-13. PMID 20555126 DOI: 10.3233/Hab-2010-0215 |
0.359 |
|
| 2010 |
Broek Ivd, Sparidans RW, Schellens JHM, Beijnen JH. Sensitive liquid chromatography/tandem mass spectrometry assay for absolute quantification of ITIH4-derived putative biomarker peptides in clinical serum samples. Rapid Communications in Mass Spectrometry. 24: 1842-1850. PMID 20533314 DOI: 10.1002/Rcm.4588 |
0.304 |
|
| 2010 |
Helgason HH, Engwegen JY, Zapatka M, Vincent A, Cats A, Boot H, Beijnen JH, Schellens JH. Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry. Oncology Reports. 24: 57-64. PMID 20514444 DOI: 10.3892/Or_00000828 |
0.478 |
|
| 2010 |
Ter Heine R, Rosing H, Beijnen JH, Huitema AD. A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 48: 1153-5. PMID 20482447 DOI: 10.1515/Cclm.2010.225 |
0.691 |
|
| 2010 |
Beijnen JH, Schellens JH. Personalized medicine in oncology: a personal view with myths and facts. Current Clinical Pharmacology. 5: 141-7. PMID 20406176 DOI: 10.2174/157488410791498789 |
0.458 |
|
| 2010 |
Leijen S, Beijnen JH, Schellens JH. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Current Clinical Pharmacology. 5: 186-91. PMID 20406171 DOI: 10.2174/157488410791498824 |
0.442 |
|
| 2010 |
Boss DS, Beijnen JH, Schellens JH. Inducing synthetic lethality using PARP inhibitors. Current Clinical Pharmacology. 5: 192-5. PMID 20406170 DOI: 10.2174/157488410791498798 |
0.462 |
|
| 2010 |
Jansen RS, Rosing H, Schellens JH, Beijnen JH. Facile small scale synthesis of nucleoside 5'-phosphate mixtures. Nucleosides, Nucleotides & Nucleic Acids. 29: 14-26. PMID 20391189 DOI: 10.1080/15257770903451546 |
0.429 |
|
| 2010 |
Oostendorp RL, Buckle T, Lambert G, Garrigue JS, Beijnen JH, Schellens JH, van Tellingen O. Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice. Investigational New Drugs. 29: 768-76. PMID 20390333 DOI: 10.1007/S10637-010-9421-7 |
0.506 |
|
| 2010 |
Blanken P, van den Brink W, Hendriks VM, Huijsman IA, Klous MG, Rook EJ, Wakelin JS, Barendrecht C, Beijnen JH, van Ree JM. Heroin-assisted treatment in the Netherlands: History, findings, and international context. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 20: S105-58. PMID 20362236 DOI: 10.1016/S0924-977X(10)70001-8 |
0.304 |
|
| 2010 |
van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Validation of a quantitative assay for human neutrophil peptide-1, -2, and -3 in human plasma and serum by liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 1085-92. PMID 20356805 DOI: 10.1016/J.Jchromb.2010.03.014 |
0.489 |
|
| 2010 |
Jansen RS, Rosing H, Kromdijk W, ter Heine R, Schellens JH, Beijnen JH. Simultaneous quantification of emtricitabine and tenofovir nucleotides in peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 621-7. PMID 20122883 DOI: 10.1016/J.Jchromb.2010.01.002 |
0.472 |
|
| 2010 |
van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 590-602. PMID 20116351 DOI: 10.1016/J.Jchromb.2010.01.011 |
0.478 |
|
| 2010 |
Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Molecular Cancer Therapeutics. 9: 319-26. PMID 20103600 DOI: 10.1158/1535-7163.Mct-09-0663 |
0.301 |
|
| 2010 |
Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Molecular Pharmacology. 77: 687-94. PMID 20086033 DOI: 10.1124/Mol.109.062364 |
0.324 |
|
| 2010 |
Vainchtein LD, Rosing H, Schellens JH, Beijnen JH. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. Biomedical Chromatography : Bmc. 24: 374-86. PMID 19650151 DOI: 10.1002/Bmc.1302 |
0.522 |
|
| 2010 |
Damen CW, Rosing H, Schellens JH, Beijnen JH. High-performance liquid chromatography coupled with mass spectrometry for the quantitative analysis of vinca-alkaloids in biological matrices: a concise survey from the literature. Biomedical Chromatography : Bmc. 24: 83-90. PMID 19606419 DOI: 10.1002/Bmc.1271 |
0.448 |
|
| 2010 |
Oostendorp RL, Witteveen PO, Schwartz B, Vainchtein LD, Schot M, Nol A, Rosing H, Beijnen JH, Voest EE, Schellens JH. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. Investigational New Drugs. 28: 163-70. PMID 19404582 DOI: 10.1007/S10637-009-9244-6 |
0.534 |
|
| 2010 |
Zandvliet AS, Karlsson MO, Schellens JH, Copalu W, Beijnen JH, Huitema AD. Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents. Investigational New Drugs. 28: 61-75. PMID 19198760 DOI: 10.1007/S10637-008-9216-2 |
0.75 |
|
| 2010 |
Fan L, Gooijer MCd, Beumer JH, Christner SM, Beijnen JH, Tellingen Ov. Abstract LB-49: ABC transporters in the blood-brain barrier limit the brain penetration of the PARP inhibitor ABT-888 Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-49 |
0.31 |
|
| 2010 |
Fan L, Gooijer MCd, Buil L, Vries NAd, Beijnen JH, Tellingen Ov. Abstract LB-301: The impact of Abcb1 and Abcg2 on the brain penetration of PI3K-mTOR inhibitors Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-301 |
0.313 |
|
| 2010 |
Tellingen Ov, Brandsma D, Appeldoorn CCM, Manca MF, Rip J, Dorland R, Kregten JMRv, Boogerd WJ, Beijnen JH, Gaillard PJ. Abstract 5537: GSH-conjugation improves efficacy of Doxil against intracranial xenografts Cancer Research. 70: 5537-5537. DOI: 10.1158/1538-7445.Am10-5537 |
0.325 |
|
| 2010 |
Teunissen S, Rosing H, Schinkel A, Schellens J, Beijnen J. Bioanalytical methods for determination of tamoxifen and its phase I metabolites: A review Analytica Chimica Acta. 683: 21-37. DOI: 10.1016/J.Aca.2010.10.009 |
0.305 |
|
| 2009 |
ter Heine R, Beijnen JH, Huitema AD. Bioanalytical issues in patient-friendly sampling methods for therapeutic drug monitoring: focus on antiretroviral drugs. Bioanalysis. 1: 1329-38. PMID 21083054 DOI: 10.4155/Bio.09.124 |
0.346 |
|
| 2009 |
Cömezoğlu SN, Ly VT, Zhang D, Humphreys WG, Bonacorsi SJ, Everett DW, Cohen MB, Gan J, Beumer JH, Beijnen JH, Schellens HM, Lappin G. Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS). Drug Metabolism and Pharmacokinetics. 24: 511-22. PMID 20045986 DOI: 10.2133/Dmpk.24.511 |
0.39 |
|
| 2009 |
Harmsen S, Meijerman I, Febus CL, Maas-Bakker RF, Beijnen JH, Schellens JH. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemotherapy and Pharmacology. 66: 765-71. PMID 20041327 DOI: 10.1007/S00280-009-1221-4 |
0.483 |
|
| 2009 |
Tran L, Beijnen JH, Huitema AD. The preparation of radiolabeled monoclonal antibodies for human use. Human Antibodies. 18: 145-56. PMID 19996529 DOI: 10.3233/Hab-2009-0211 |
0.66 |
|
| 2009 |
Koolen SL, Beijnen JH, Schellens JH. Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. Clinical Pharmacology and Therapeutics. 87: 126-9. PMID 19924122 DOI: 10.1038/Clpt.2009.233 |
0.509 |
|
| 2009 |
van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, Rooswinkel RW, van Tellingen O, Rosing H, Beijnen JH, Schinkel AH. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Research. 69: 8996-9002. PMID 19920203 DOI: 10.1158/0008-5472.Can-09-2915 |
0.334 |
|
| 2009 |
Sparidans RW, Iusuf D, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 4090-6. PMID 19910267 DOI: 10.1016/J.Jchromb.2009.10.024 |
0.506 |
|
| 2009 |
Gast MC, van Dulken EJ, van Loenen TK, Kingma-Vegter F, Westerga J, Flohil CC, Knol JC, Jimenez CR, van Gils CH, Wessels LF, Schellens JH, Beijnen JH. Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling. The International Journal of Biological Markers. 24: 130-41. PMID 19787623 DOI: 10.5301/Jbm.2009.3475 |
0.444 |
|
| 2009 |
Lankheet AG, Hillebrand MJ, Langenberg MH, Rosing H, Huitema AD, Voest EE, Schellens JH, Beijnen JH. A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 3625-30. PMID 19762293 DOI: 10.1016/J.Jchromb.2009.09.001 |
0.521 |
|
| 2009 |
van Waterschoot RA, Rooswinkel RW, Sparidans RW, van Herwaarden AE, Beijnen JH, Schinkel AH. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 2305-13. PMID 19752211 DOI: 10.1124/Dmd.109.029397 |
0.323 |
|
| 2009 |
Pluim D, Beijnen JH, Schellens JH, van Tellingen O. Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 3549-55. PMID 19744901 DOI: 10.1016/J.Jchromb.2009.08.035 |
0.505 |
|
| 2009 |
Damen CW, Chen W, Chakraborty AB, van Oosterhout M, Mazzeo JR, Gebler JC, Schellens JH, Rosing H, Beijnen JH. Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. Journal of the American Society For Mass Spectrometry. 20: 2021-33. PMID 19744865 DOI: 10.1016/J.Jasms.2009.07.017 |
0.434 |
|
| 2009 |
Damen CW, Schellens JH, Beijnen JH. Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. Human Antibodies. 18: 47-73. PMID 19729801 DOI: 10.3233/Hab-2009-0206 |
0.476 |
|
| 2009 |
Koolen SL, Huitema AD, Jansen RS, van Voorthuizen T, Beijnen JH, Smit WM, Schellens JH. Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature. The Oncologist. 14: 944-8. PMID 19726456 DOI: 10.1634/Theoncologist.2009-0111 |
0.757 |
|
| 2009 |
Jansen RS, Rosing H, Schellens JH, Beijnen JH. Simultaneous quantification of 2',2'-difluorodeoxycytidine and 2',2'-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 23: 3040-50. PMID 19705384 DOI: 10.1002/Rcm.4212 |
0.472 |
|
| 2009 |
Jansen RS, Rosing H, Schellens JH, Beijnen JH. Protein versus DNA as a marker for peripheral blood mononuclear cell counting. Analytical and Bioanalytical Chemistry. 395: 863-7. PMID 19685233 DOI: 10.1007/S00216-009-3022-3 |
0.427 |
|
| 2009 |
Boss DS, Beijnen JH, Schellens JH. Clinical experience with aurora kinase inhibitors: a review. The Oncologist. 14: 780-93. PMID 19684075 DOI: 10.1634/Theoncologist.2009-0019 |
0.433 |
|
| 2009 |
Teunissen SF, Rosing H, Koornstra RH, Linn SC, Schellens JH, Schinkel AH, Beijnen JH. Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 2519-29. PMID 19589736 DOI: 10.1016/J.Jchromb.2009.06.029 |
0.526 |
|
| 2009 |
Engwegen JY, Mehra N, Haanen JB, Schellens JH, Voest EE, Beijnen JH. Identification of two new serum protein profiles for renal cell carcinoma. Oncology Reports. 22: 401-8. PMID 19578783 |
0.359 |
|
| 2009 |
ter Heine R, Hillebrand MJ, Rosing H, van Gorp EC, Mulder JW, Beijnen JH, Huitema AD. Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 1826-40. PMID 19546238 DOI: 10.1124/Dmd.109.028258 |
0.333 |
|
| 2009 |
Boss DS, Siegel-Lakhai WS, van Egmond-Schoemaker NE, Pluim D, Rosing H, Ten Bokkel Huinink WW, Beijnen JH, Schellens JH. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4475-83. PMID 19531625 DOI: 10.1158/1078-0432.Ccr-08-3144 |
0.508 |
|
| 2009 |
Damen CW, Speijer H, Hermens WT, Schellens JH, Rosing H, Beijnen JH. The bioanalysis of trastuzumab in human serum using precipitate-enhanced ellipsometry. Analytical Biochemistry. 393: 73-9. PMID 19523916 DOI: 10.1016/J.Ab.2009.06.006 |
0.462 |
|
| 2009 |
Gast MC, Van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, Schellens JH, Beijnen JH. Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. Oncology Reports. 22: 205-13. PMID 19513525 DOI: 10.3892/Or_00000426 |
0.452 |
|
| 2009 |
Oostendorp RL, Huitema A, Rosing H, Jansen RS, Ter Heine R, Keessen M, Beijnen JH, Schellens JH. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4228-33. PMID 19509162 DOI: 10.1158/1078-0432.Ccr-08-2944 |
0.734 |
|
| 2009 |
Damen CWN, Lagas JS, Rosing H, Schellens JHM, Beijnen JH. The bioanalysis of vinorelbine and 4-O-deacetylvinorelbine in human and mouse plasma using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass-spectrometry. Biomedical Chromatography. 23: 1316-1325. PMID 19488983 DOI: 10.1002/Bmc.1255 |
0.305 |
|
| 2009 |
Damen CW, Derissen EJ, Schellens JH, Rosing H, Beijnen JH. The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum. Journal of Pharmaceutical and Biomedical Analysis. 50: 861-6. PMID 19487098 DOI: 10.1016/J.Jpba.2009.04.031 |
0.455 |
|
| 2009 |
Damen CW, de Groot ER, Heij M, Boss DS, Schellens JH, Rosing H, Beijnen JH, Aarden LA. Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma. Analytical Biochemistry. 391: 114-20. PMID 19464994 DOI: 10.1016/J.Ab.2009.05.030 |
0.48 |
|
| 2009 |
Ter Heine R, Huitema AD, Jansen RS, Smits PH, van Gorp EC, Wagenaar JF, Beijnen JH, Mulder JW. Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure. Antiviral Therapy. 14: 299-301. PMID 19430105 |
0.636 |
|
| 2009 |
Gast MC, van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, Schellens JH, Beijnen JH. Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS). Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 47: 694-705. PMID 19416081 DOI: 10.1515/Cclm.2009.151 |
0.456 |
|
| 2009 |
Damen CW, Rosing H, Schellens JH, Beijnen JH. Application of dried blood spots combined with high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry for simultaneous quantification of vincristine and actinomycin-D. Analytical and Bioanalytical Chemistry. 394: 1171-82. PMID 19387621 DOI: 10.1007/S00216-009-2775-Z |
0.472 |
|
| 2009 |
Brouwers EE, Huitema AD, Boogerd W, Beijnen JH, Schellens JH. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncologica (Stockholm, Sweden). 48: 832-41. PMID 19308757 DOI: 10.1080/02841860902806609 |
0.737 |
|
| 2009 |
Tran L, Baars JW, Maessen HJ, Hoefnagel CA, Beijnen JH, Huitema AD. A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy. Cancer Biotherapy & Radiopharmaceuticals. 24: 103-10. PMID 19243252 DOI: 10.1089/Cbr.2008.0538 |
0.695 |
|
| 2009 |
Beumer JH, Franke NE, Tolboom R, Buckle T, Rosing H, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O. Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. Investigational New Drugs. 28: 145-55. PMID 19238326 DOI: 10.1007/S10637-009-9234-8 |
0.46 |
|
| 2009 |
Jansen RS, Rosing H, Schellens JH, Beijnen JH. Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: development of a liquid chromatography-tandem mass spectrometry method. Journal of Chromatography. A. 1216: 3168-74. PMID 19237159 DOI: 10.1016/J.Chroma.2009.02.002 |
0.428 |
|
| Show low-probability matches. |
